

World Journal of *Gastrointestinal Endoscopy*

World J Gastrointest Endosc 2011 March 16; 3(3): 49-66



Editorial Board

2009-2013

The World Journal of Gastrointestinal Endoscopy Editorial Board consists of 400 members, representing a team of worldwide experts in gastrointestinal endoscopy. They are from 45 countries, including Australia (7), Austria (1), Belgium (6), Brazil (7), Canada (5), Chile (2), China (26), Croatia (2), Cuba (1), Czech Republic (3), Denmark (1), Ecuador (1), Egypt (1), Finland (2), France (10), Germany (27), Greece (11), Hungary (4), India (15), Iran (2), Ireland (2), Israel (6), Italy (37), Japan (62), Lebanon (1), Lithuania (1), Malaysia (2), Mexico (1), Netherlands (6), New Zealand (1), Norway (2), Pakistan (2), Poland (2), Portugal (5), Romania (2), Singapore (2), South Africa (1), South Korea (13), Spain (17), Sweden (3), Thailand (5), Turkey (8), United Arab Emirates (1), United Kingdom (15), and United States (69).

PRESIDENT AND EDITOR-IN-CHIEF

Lian-Sheng Ma, *Beijing*

STRATEGY ASSOCIATE EDITORS-IN-CHIEF

Kazuya Akahoshi, *Iizuka*
William Robert Brugge, *Massachusetts*
Qiang Cai, *Georgia*
Juan J Vila Costas, *Pamplona*
Atsushi Irisawa, *Fukushima*
Andreas Sieg, *Heidelberg*
Gaetana Ilaria Tarantino, *Palermo*
Tony CK Tham, *Northern Ireland*
Konstantinos Triantafyllou, *Haidari*

GUEST EDITORIAL BOARD MEMBERS

Zhong-Ming Bai, *Taipei*
Wai-Keung Chow, *Taichung*
Wei-Hung Chan, *Taipei*
Yang-Yuan Chen, *Changhua*
Yen-Chang Chu, *Taichung*
Hwai-Jeng Lin, *Changhua*
Mei-Yung Tsou, *Taipei*
Bor-Shyang Sheu, *Tainan*
Ming-Yao Su, *Taoyuan*
Deng-Chyang Wu, *Kaohsiung*
Hsiu-Po Wang, *Taipei*
Ming-Shiang Wu, *Taipei*
Sheng-Lei Yan, *Tainan*

MEMBERS OF THE EDITORIAL BOARD



Australia

Hong-Chun Bao, *Victoria*

Michael J Bourke, *Sydney*
Ian C Lawrance, *Western Australia*
Rupert W Leong, *Concord*
Liang Qiao, *Westmead*
Michael Swan, *Victoria*
Rajvinder Singh, *South Australia*



Austria

Christine Kapral, *Linz*



Belgium

Giovanni Dapri, *Brussels*
Pierre Henri Deprez, *Brussels*
Christophe Moreno, *Brussel*
Tom G Moreels, *Antwerp*
Werner Van Steenberghe, *Leuven*
Daniel Urbain, *Brussels*



Brazil

Everson LA Artifon, *São Paulo*
Fátima Figueiredo, *Rio de Janeiro*
Fauze Maluf-Filho, *São Paulo*
Fernando Fornari, *Passo Fundo*
Joaquim PPM Filho, *São Paulo*
José Luiz Sebba Souza, *São Paulo*
Claudio R Teixeira, *Porto Alegre*



Canada

Majid A Al Madi, *Montreal*

F Douglas Bair, *Ontario*
André Roy, *Québec*
Alan A Weiss, *Vancouver*
Brian Michael Yan, *Alberta*



Chile

Paul Richard Harris, *Marcoleta*
Italo FB Miranda, *Santiago*



China

Annie On On Chan, *Hong Kong*
Philip WY Chiu, *Hong Kong*
Jin Gu, *Beijing*
Simon Law, *Hong Kong*
Fu-Yu Li, *Chengdu*
Ka Ho Lok, *Hong Kong*
Tian-Le Ma, *Shanghai*
Si-Yu Sun, *Shenyang*
Anthony YB Teoh, *Shatin*
Kenneth KY Wong, *Hong Kong*
Jia-Ju Zheng, *Suzhou*
Jiang-Fan Zhu, *Shanghai*



Croatia

Josip Bago, *Zagreb*
Nadan Rustemović, *Zagreb*



Cuba

Damian C Rodriguez, *Havana*



Czech Republic

Marcela Kopacova, *Hradec Kralove*
Michal Procke, *Prague*
Miroslav Zavoral, *Prague*



Denmark

Peter Bytzer, *Koegel*



Ecuador

Carlos Robles-Medranda, *Portoviejo*



Egypt

Nabil Ali Gad El-Hak, *Mansoura*



Finland

Paulina Salminen, *Turku*
Lars Mikael Victorzon, *Vaasa*



France

Romain Coriat, *Paris*
Bernard G Dallemagne, *Strasbourg*
Gerard Jean Gay, *Vandoeuvre les Nancy*
Lesur Gilles, *Boulogne*
René Lambert, *Lyon*
Sylvain Manfredi, *Rennes*
Barthet Marc, *Marseille Cedex*
JF Rey, *Saint Laurent Du Var Cedex*
José Sahel, *Marseille*
Nathalie Salles, *Pessac*



Germany

Marcel Binnebösel, *Aachen*
P Born, *Munich*
Stefan von Delius, *München*
Dirk Domagk, *Muenster*
Christoph Eisenbach, *Heidelberg*
Ines Gockel, *Mainz*
Arthur Hoffman, *Mainz*
Georg FBA Kähler, *Mannheim*
Günter Kampf, *Hamburg*
Ralf Kiesslich, *Mainz*
Andreas Kirschniak, *Tübingen*
Oliver Pech, *Wiesbaden*
Michael Pietsch, *Mainz*
Andreas Probst, *Augsburg*
Andrea Riphaus, *Bochum*
Raphael Rosch, *Aachen*
Claus Schäfer, *Munich*
Hubert J Scheidbach, *Magdeburg*
Peter Schemmer, *Heidelberg*
Hans Scherübl, *Berlin*
Thomas W Spahn, *Schwerte*
Holger Sudhoff, *Bielefeld*

Jens Tischendorf, *Aachen*
Michael Vieth, *Bayreuth*
Jochen Wedemeyer, *Hannover*
Uwe Will, *Gera*



Greece

Georgios K Anagnostopoulos, *Athens*
Anna Eleftheriadou, *Rethymnon*
Dimitris K Iakovidis, *Lamia*
Dimitrios Kapetanios, *Thessaloniki*
John A Karagiannis, *Athens*
Stefanos Karagiannis, *Kifissia*
Spiros D Ladas, *Athens*
Konstantinos A Papadakis, *Heraklion*
George H Sakorafas, *Athens*
Elias Xirouchakis, *Areos*



Hungary

Pal Demeter, *Budapest*
Lujber László, *Pecs*
Peter Lakatos, *Budapest*
István Rác, *Gyor*



India

Ramanathan S Bharathi, *Uttar Pradesh*
Devendra C Desai, *Mumbai*
Evan L Fogel, *Indianapolis*
Uday Chand Ghoshal, *Lucknow*
Chittor M Habibullah, *Andhra Pradesh*
Rakesh Kochhar, *Chandigarh*
Rakesh Kumar, *New Delhi*
Sri Prakash Misra, *Allahabad*
Sandeep Nijhawan, *Rajasthan*
Kaushal Kishor Prasad, *Chandigarh*
Surinder Singh Rana, *Chandigarh*
Muthukumaran Rangarajan, *Tamil Nadu*
D Nageshwar Reddy, *Hyderabad*
Omar Javed Shah, *Kashmir*
Virendra Singh, *Chandigarh*



Iran

Tahereh Falsafi, *Tehran*
Mohammad Rahnvardi, *Tehran*



Ireland

Colm Ó'Moráin, *Dublin*
Eamonn M Quigley, *Cork*



Israel

Simon Bar-Meir, *Ramat Gan*
Rami Eliakim, *Haifa*
Zvi Fireman, *Hadea*
Irina Hirsh, *Haifa*

Tiberiu Hershcovici, *Jerusalem*
Jesse Lachter, *Haifa*



Italy

Paola De Angelis, *Rome*
Paolo G Arcidiacono, *Milan*
Alberto Arezzo, *Torino*
Gabrio Bassotti, *San Sisto*
Giampaolo Bresci, *Pisa*
Carlo Calabrese, *Bologna*
Salvatore MA Campo, *Rome*
Federico Carpi, *Pisa*
Livio Cipolletta, *Torre del Greco*
Sandro Contini, *Parma*
Salvatore Cucchiara, *Rome*
Gabriele Curcio, *Palermo*
Luigi Familiari, *Cavalluccio*
Lorenzo Fuccio, *Bologna*
Giuseppe Galloro, *Napoli*
Giovanni B Gasbarrini, *Rome*
Carlo M Girelli, *Busto Arsizio*
Mauro Manno, *Baggiovara di Modena*
Hugo Martines, *Savona*
Gabriele Masselli, *Rome*
Emanuele Meroni, *Milan*
Andrea Moglia, *Pisa*
Raffaele Pezzilli, *Bologna*
Venerino Poletti, *Forli*
Salvatore Pucciarelli, *Padova*
Franco Radaelli, *Como*
Marmo Riccardo, *Luigi Curto Polla*
Maria Elena Riccioni, *Rome*
Stefania Romano, *Naples*
Emanuele Rondonotti, *Milano*
Gianluca Rotondano, *Torre del Greco*
Vittorio Terruzzi, *Como*
Cristina Trovato, *Milano*
Antonio Tucci, *Bologna*
Maurizio Vecchi, *Milan*
Maurizio Ventrucci, *Bologna*



Japan

Mitsuhiro Asakuma, *Osaka*
Hiroki Endo, *Kanagawa*
Shotaro Enomoto, *Wakayama*
Kuang-I Fu, *Kashiwa*
Makoto Hashizume, *Fukuoka*
Toru Hiyama, *Higashihiroshima*
Akira Hokama, *Okinawa*
Akira Horiuchi, *Komagane*
Kinichi Hotta, *Nagano*
Atsushi Imagawa, *Kagawa*
Hiroo Imazu, *Tokyo*
Haruhiro Inoue, *Yokohama*
Ryu Ishihara, *Osaka*
Naoki Ishii, *Tokyo*
Hajime Isomoto, *Nagasaki*
Takao Itoi, *Tokyo*
Satoru Kakizaki, *Gunma*
Hiroshi Kakutani, *Tokyo*
Terumi Kamisawa, *Tokyo*
Yoshihide Kanno, *Sendai*
Mototsugu Kato, *Sapporo*
Takashi Kawai, *Tokyo*

Hirofumi Kawamoto, *Okayama*
 Hiroto Kita, *Saitama*
 Koga Komatsu, *Akita*
 Hitoshi Kondo, *Sapporo*
 Hiroaki Kubo, *Fukuoka*
 Keiichiro Kume, *Kitakyusyu*
 Iruru Maetani, *Tokyo*
 Hiroto Miwa, *Hyogo*
 Akihiro Mori, *Aichi*
 Akihiro Mori, *Aichi*
 Yoshihiro Moriwaki, *Yokohama*
 Naoki Muguruma, *Tokushima*
 Shinji Nishiwaki, *Gifu*
 Ichiro Oda, *Tokyo*
 Kazuichi Okazaki, *Osaka*
 Yasuhiro Oono, *Chiba*
 Taro Osada, *Tokyo*
 Yutaka Saito, *Tokyo*
 Yuzo Sakai, *Chiba*
 Naoto Sakamoto, *Tokyo*
 Nobuyuki Sakurazawa, *Tokyo*
 Yasushi Sano, *Hyogo*
 Tomoyuki Shibata, *Toyoake*
 Takashi Shida, *Chiba*
 Atsushi Sofuni, *Tokyo*
 Kazuki Sumiyama, *Tokyo*
 Nobumi Tagaya, *Tochigi*
 Hirokazu Takahashi, *Yokohama*
 Kyosuke Tanaka, *Mie*
 Shinji Tanaka, *Hiroshima*
 Gen Tohda, *Fukui*
 Tomoyuki Tsujikawa, *Shiga*
 Noriya Uedo, *Osaka*
 Shuji Yamamoto, *Kyoto*
 Takayuki Yamamoto, *Yokkaichi*
 Hideo Yanai, *Yamaguchi*
 Kenjiro Yasud, *Kyoto*
 Naohisa Yoshida, *Kyoto*



Lebanon

Kassem A Barada, *Beirut*



Lithuania

Laimas Virginijus Jonaitis, *Kaunas*



Malaysia

Sanjiv Mahadeva, *Kuala Lumpur*
 Sreenivasan Sasidharan, *Pulau Pinang*



Mexico

OT Teramoto-Matsubara, *México*



Netherlands

Marco Bruno, *Rotterdam*
 Dirk Joan Gouma, *Amsterdam*
 Iris Lansdorp-Vogelaar, *Rotterdam*
 Chris JJ Mulder, *Amsterdam*

Vasileios Panteris, *Rotterdam*
 Harald Erwin Vonkeman, *Enschede*



New Zealand

Michael PG Schultz, *Dunedin*



Norway

Magdy El-Salhy, *Stord*
 Odd Helge Gilja, *Bergen*



Pakistan

Syed H Ali Shah, *Karachi*
 Lubna Kamani, *Karachi*



Poland

Stanislaw A Hac, *Gdansk*
 Maciej Michalik, *Pomorskie*



Portugal

Miguel T Coimbra, *Porto*
 Marie I Cremers, *Setúbal*
 Mário Dinis-Ribeiro, *Porto*
 Pedro N Figueiredo, *Coimbra*
 Rui MA da Silva, *Porto*



Romania

Mihai Ciocirlan, *Bucharest*
 Lucian Negreanu, *Bucharest*



Singapore

Zhiwei Huang, *Singapore*
 Surendra K Mantoo, *Singapore*



South Africa

Roland N Ndip, *Alice*



South Korea

Young-Tae Bak, *Seoul*
 Dong Kyung Chang, *Seoul*
 Youn-Seok Cho, *UiJeongbu*
 Seong Woo Jeon, *Daegu*
 Jong-Man Kang, *Seoul*
 Yong Sung Kim, *Gyeonggi-do*
 Hang Lak Lee, *Sungdonggu*
 Suck-Ho Lee, *Cheonan*
 Jong Ho Moon, *Bucheon*
 Dong Kyun Park, *Incheon*
 Dae Kyung Sohn, *Gyeonggi*

Jaekyu Sung, *Daejeon*
 Si-Young Song, *Seoul*



Spain

Jose FN Aguilar, *Palma*
 Adolfo P Blanco, *Asturias*
 Andres Cardenas, *Barcelona*
 Gloria Fernández-Esparrach, *Barcelona*
 Jesús García-Cano, *Cuenca*
 Angels Gines, *Barcelona*
 Angel Lanas, *Zaragoza*
 G Payeras Llodrá, *Madrid*
 Alfredo José Lucendo, *Tomelloso*
 Enrique F Perez-Cuadrado Martinez, *Murcia*
 Luis Rabago, *Madrid*
 Eduardo Redondo-Cerezo, *Cuenca*
 Luis Rodrigo, *Oviedo*
 Jaume Boix Valverde, *Badalona*
 Josep Llach Vila, *Barcelona*
 Santiago Vivas, *León*



Sweden

George Dafnis, *Eskilstuna*
 Per-Ola Park, *Borås*
 Carlos A Rubio, *Stockholm*



Thailand

Somchai Amornytin, *Bangkok*
 Thawatchai Akaraviputh, *Bangkok*
 Udom Kachintorn, *Bangkok*
 Varut Lohsirawat, *Bangkok*
 Rungsun Rerknimitr, *Bangkok*



Turkey

Selcuk Disibeyaz, *Nkara*
 Mehmet Eken, *Istanbul*
 Muammer Kara, *Ankara*
 Taylan Kav, *Ankara*
 Nevin Oruc, *İzmir*
 Burhan Ozdil, *Adana*
 Nurdan Ozmeric, *Emek Ankara*
 Sema Zer Toros, *Istanbul*



United Arab Emirates

Margit Gabriele Muller, *Abu Dhabi*



United Kingdom

Basil J Ammori, *Manchester*
 Simon HC Anderson, *London*
 Adam D Farmer, *London*
 Annette Fritscher-Ravens, *Landon*
 Gianpiero Gravante, *Bristol*
 Abdulzahra Hussain, *London*
 United KV Kodogiannis, *London*
 Seamus J Murphy, *Newry*
 Perminder Phull, *Aberdeen*

Krish Ragnath, *Nottingham*
Jayesh Sagar, *Wishaw*
Reena Sidhu, *Sheffield*
Adrian J Stanley, *Glasgow*
Hu Zhang, *Cambridge*



United States

Maher Aref Abbas, *Los Angeles*
Douglas G Adler, *Utah*
Deepak Agrawal, *Dallas*
Mohammad Al-Haddad, *Indianapolis*
Jamie S Barkin, *Florida*
Pedro W Baron, *Loma Linda*
James Stephen Barthel, *Florida*
Neil Bhattacharyya, *Boston*
Juliane Bingener-Casey, *Rochester*
Cheri Lee Canon, *Birmingham*
Sherman M Chamberlain, *Georgia*
Lawrence B Cohen, *New York*
Lawrence Bruce Cohen, *New York*
Paul G Curcillo II, *Philadelphia*
Kiron M Daskiron, *New Brunswick*
David J Desilets, *Springfield*

John C Deutsch, *Duluth*
Peter Draganov, *Gainesville*
Viktor Ernst Eysselein, *Torrance*
Daniel L Farkas, *Los Angeles*
Ronnie Fass, *Southern Arizona*
Georg Feldmann, *Maryland*
Raja M Flores, *New York*
Catherine T Frenette, *San Francisco*
David Friedel, *New York*
Ronnie Fass, *Tucson*
Seng-Ian Gan, *Seattle*
Denise W Gee, *Massachusetts*
Samuel A Giday, *Maryland*
George F Gowen, *Pottstown*
Sammy Ho, *New York*
Moises Jacobs, *Florida*
Robert Thomas Jensen, *Bethesda*
Michel Kahaleh, *Virginia*
Peter James Kahrilas, *Suite*
Sergey V Kantsevov, *Baltimore*
Christopher Lawrence, *Charleston*
Felix W Leung, *Sepulveda*
Simon K Lo, *California*
Charles Maltz, *New York*
Jeffrey Michael Marks, *Ohio*
Hiroshi Mashimo, *Massachusetts*

Abraham Mathew, *Hershey*
James M Mullin, *Wynneville*
Harvey J Murff, *Nashville*
Koichi Nagata, *Boston*
Ying-Tian Pan, *Stony Brook*
Jitesh A Patel, *Pittsburgh*
Massimo Raimondo, *Jacksonville*
Amit Rastogi, *Kansas City*
Robert J Richards, *New York*
Praveen Roy, *New Mexico*
David T Rubin, *Chicago*
Enrique Seoane-Vazquez, *Columbus*
Prateek Sharma, *Kansas*
Bo Shen, *Ohio*
Danny A Sherwinter, *Brooklyn*
Andrew Ukleja, *Weston*
Bennie Ray Upchurch, *Ohio*
Shyam Varadarajulu, *Alabama*
Marcelo F Vela, *South Carolina*
Wahid Wassef, *Worcester*
Irving Waxman, *Illinois*
C Mel Wilcox, *Alabama*
Field Farrar Willingham, *Massachusetts*
Timothy A Woodward, *Jacksonville*
Shuhei Yoshida, *Massachusetts*

ACKNOWLEDGMENTS I Acknowledgments to reviewers of *World Journal of Gastrointestinal Endoscopy*

APPENDIX I Meetings
I-V Instructions to authors

ABOUT COVER Ridditid W, Rerknimitr R, Amornsawadwattana S, Ponauthai Y, Kullavanijaya P. Stent-in-stent through a side hole to prevent biliary metallic stent migration *World J Gastrointest Endosc* 2011; 3(3): 64-66
<http://www.wjgnet.com/1948-5190/full/v3/i3/64.htm>

AIM AND SCOPE *World Journal of Gastrointestinal Endoscopy* (*World J Gastrointest Endosc*, *WJGE*, online ISSN 1948-5190, DOI: 10.4253), is a monthly, open-access, peer-reviewed journal supported by an editorial board of 400 experts in gastrointestinal endoscopy from 45 countries.
The major task of *WJGE* is to report rapidly the most recent results in basic and clinical research on gastrointestinal endoscopy including: gastroscopy, intestinal endoscopy, colonoscopy, capsule endoscopy, laparoscopy, interventional diagnosis and therapy, as well as advances in technology. Emphasis is placed on the clinical practice of treating gastrointestinal diseases with or under endoscopy. Papers on advances and application of endoscopy-associated techniques, such as endoscopic ultrasonography, endoscopic retrograde cholangiopancreatography, endoscopic submucosal dissection and endoscopic balloon dilation are also welcome.

FLYLEAF I-IV Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Le Zhang*
Responsible Electronic Editor: *Le Zhang*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Hai-Ning Zhang*
Proofing Editorial Office Director: *Hai-Ning Zhang*

NAME OF JOURNAL
World Journal of Gastrointestinal Endoscopy

LAUNCH DATE
October 15, 2009

SPONSOR
Beijing Baishideng BioMed Scientific Co., Ltd., Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China
Telephone: +86-10-8538-1892
Fax: +86-10-8538-1893
E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

EDITING
Editorial Board of *World Journal of Gastrointestinal Endoscopy*, Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China
Telephone: +86-10-5908-0038
Fax: +86-10-8538-1893
E-mail: wjge@wjgnet.com
<http://www.wjgnet.com>

PUBLISHING
Baishideng Publishing Group Co., Limited, Room 1701, 17/F, Henan Building, No.90 Jaffe Road, Wanchai, Hong Kong, China
Fax: 00852-3115-8812
Telephone: 00852-5804-2046
E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

SUBSCRIPTION
Beijing Baishideng BioMed Scientific Co., Ltd., Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China
Telephone: +86-10-8538-1892
Fax: +86-10-8538-1893
E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

ONLINE SUBSCRIPTION
One-Year Price: 216.00 USD

PUBLICATION DATE
March 16, 2011

SERIAL PUBLICATION NUMBER
ISSN 1948-5190 (online)

PRESIDENT AND EDITOR-IN-CHIEF
Lian-Sheng Ma, Beijing

STRATEGY ASSOCIATE EDITORS-IN-CHIEF
Kazuya Akahoshi, Iizuka
William Robert Brugge, Massachusetts
Qiang Cai, Georgia
Juan J Vila Costas, Pamplona
Atsushi Irisawa, Fukushima
Andreas Sieg, Heidelberg
Gaetana Ilaria Tarantino, Palermo
Tony CK Tham, Northern Ireland
Konstantinos Triantafyllou, Haidari

EDITORIAL OFFICE
Hai-Ning Zhang, Director
World Journal of Gastrointestinal Endoscopy
Room 903, Building D, Ocean International Center, No. 62 Dongsihuan Zhonglu, Chaoyang District, Beijing 100025, China
Telephone: +86-10-5908-0038
Fax: +86-10-8538-1893
E-mail: wjge@wjgnet.com
<http://www.wjgnet.com>

COPYRIGHT
© 2011 Baishideng. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

INSTRUCTIONS TO AUTHORS
Full instructions are available online at http://www.wjgnet.com/1948-5190/g_info_20100316080002.htm. If you do not have web access please contact the editorial office.

ONLINE SUBMISSION
<http://www.wjgnet.com/1948-5190/office/>

Intravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits

Hsiu-Chi Cheng, Bor-Shyang Sheu

Hsiu-Chi Cheng, Bor-Shyang Sheu, Institute of Clinical Medicine, Medical College, National Cheng Kung University, Tainan 70428, Taiwan, China

Hsiu-Chi Cheng, Bor-Shyang Sheu, Department of Internal Medicine, National Cheng Kung University, Tainan 70428, Taiwan, China

Author contributions: Cheng HC composed the review with thoughtful discussion and refinement of the manuscript by Sheu BS.

Correspondence to: Bor-Shyang Sheu, MD, Professor of Internal Medicine, National Cheng Kung University Hospital, 138 Sheng Li Road, Tainan 70428, Taiwan, China. sheubs@mail.ncku.edu.tw

Telephone: +886-6-2353535 Fax: +886-6-2370941

Received: November 27, 2010 Revised: February 22, 2011

Accepted: March 1, 2011

Published online: March 16, 2011

Abstract

Peptic ulcer bleeding is a common disease and recurrent bleeding is an independent risk factor of mortality. Infusion with proton pump inhibitors (PPIs) prevents recurrent bleeding after successful endoscopic therapy. A gastric acidic environment of less than pH 5.4 alters coagulation function and activates pepsin to disaggregate platelet plugs. Gastric acid is secreted by H⁺, K⁺-ATPase, naming the proton pump. This update review focuses on the mechanism and the role of PPIs in the clinical management of patients with peptic ulcer bleeding. An intravenous omeprazole bolus followed by high-dose continuous infusion for 72 h after successful endoscopic therapy can prevent the recurrent bleeding. In the Asian, however, the infusion dosage can possibly be diminished whilst preserving favorable control of the intragastric pH and thereby still decreasing rates of recurrent bleeding. Irrespective of the infusion dosage of PPIs, rates of recurrent bleeding remain high in patients with co-morbidities. Because recurrent peptic ulcer bleeding may be prolonged in those with co-morbidities, a low-dose infusion of IV PPIs for up to 7-day may result in

better control of recurrent bleeding of peptic ulcers. Due to the inter-patient variability in CYP2C19 genotypes, the infusion form of new generation PPIs, such as esomeprazole, should be promising for the prevention of recurrent bleeding. This article offers a comprehensive review of clinical practice, highlighting the indication, the optimal dosage, the duration, and the potential limitation of PPIs infusion for peptic ulcer bleeding.

© 2011 Baishideng. All rights reserved.

Key words: Peptic ulcer bleeding; Recurrent bleeding; Comorbidity; Cytochrome P-450 2C19; Proton pump inhibitor; Omeprazole

Peer reviewers: Michal Procke, MD, Department of Internal Medicine - Gastroenterology and Endoscopy, Charles University, second Medical School, Motol University Hospital, Prague, Czech Republic; Lucian Negreanu, MD, PhD, Assistant Professor, Gastroenterology Department, Emergency University Hospital, Carol Davila University Bucharest, 169 splaiul Independentei Street, Sector 5, Bucharest, Romania

Cheng HC, Sheu BS. Intravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits. *World J Gastrointest Endosc* 2011; 3(3): 49-56 Available from: URL: <http://www.wjgnet.com/1948-5190/full/v3/i3/49.htm> DOI: <http://dx.doi.org/10.4253/wjge.v3.i3.49>

INTRODUCTION

Upper gastrointestinal bleeding is a rather common disease with prevalence rates of up to 102 per 100 000 people^[1,2]. About 48% of upper gastrointestinal bleeding is related to peptic ulcer diseases^[3]. Peptic ulcer bleeding is a potentially lethal disease, and recurrent bleeding is a considered and independent risk factor potentially leading to mortality^[4,5]. Recurrent bleeding is positively linked with the presence of stigmata of recent hemorrhage, co-morbidities, and others^[1,5-10]. In general, patients with underlying medical

co-morbidities have increased rates of recurrent bleeding and longer duration of risk for recurrent bleeding than those without co-morbidity^[6,10].

Because the acid environment of stomach is rather hostile for ulcer healing, the clinical course of peptic ulcer bleeding is more complicated than skin wound bleeding. The recurrent bleeding rate of peptic ulcers varies widely, from as low as only 5% up to almost 100%^[11]. Inhibition of gastric acid secretion by intravenous infusion of proton pump inhibitors (PPIs) has now been shown to prevent the recurrent bleeding after successful endoscopic therapy^[12-15]. However, the mortality rate of peptic ulcer bleeding has still not decreased even after PPIs usage. Yavorski *et al* found that almost all patients who died from peptic ulcer bleeding have at least one underlying comorbid illness, and the major cause of mortality is thus the underlying comorbid illness which is exacerbated by peptic ulcer bleeding or recurrent bleeding^[1]. Accordingly, it is very important to identify high risk patients with comorbidity. For such patients, the more aggressive application of intravenous (IV) PPI could be warranted to control the bleeding and also to prevent recurrent bleeding.

This article offers a comprehensive review of clinical practice highlighting the indication, the optimal dosage, the duration, and the potential limitation of PPIs infusion for peptic ulcer bleeding.

MECHANISM OF PROTON PUMP INHIBITORS

The risk of recurrent bleeding is higher and there is a more complicated healing process in peptic ulcer disease than in cutaneous wounds^[11]. The major reason for this is the acid microenvironment of the stomach lumen. Intra-gastric hydrochloric acid (HCl) which provides the acid microenvironment is secreted by H⁺, K⁺-ATPase, which is a membrane-bound proton pump in parietal cells. The proton pump is an α , β heterodimer^[16]. After parietal cells are activated on receptors, proton pumps translocate from tubulovesicles to the membranes of secretory canaliculi^[16-18].

The gastric H⁺, K⁺-ATPase is an important target for development of drugs to inhibit gastric acid secretion^[19,20]. Substitutes benzimidazoles are the first group of anti-secretory drugs, acting *via* inhibition of H⁺, K⁺-ATPase^[21,22]. Omeprazole was the first benzimidazole to be launched for clinical use in the late 1980s^[23-25]. Other analogues such as lansoprazole, rabeprazole, pantoprazole and esomeprazole have since been developed. These drugs are generically called PPIs.

PPIs are lipophilic and are inactive in the neutral environment of the bloodstream. After absorption, PPIs cross the plasma membrane, enter and accumulate in the secretory canaliculi of parietal cells, where they are protonated by acid, then converted into the active form, sulfenamide^[26,27]. The activated sulfenamide reacts covalently with the cysteine sulfhydryl group on the extracellular surface of the α -subunit, the Src homology

group of proton pumps, thus inactivates the pump and inhibits gastric acid secretion^[25,28]. PPIs are very specific to inhibition of gastric proton pumps because they are activated only in the acidic environment of the stomach, whereas they are not activated for the similar enzyme found in the colon and the kidney^[29].

INDICATIONS OF IV PPIs

Recurrent bleeding is an independent risk factor of mortality^[4] and remains at a rate of about 15% to 20% even after endoscopic hemostasis. Therefore, the aim of acute treatment of peptic ulcer bleeding is to reduce recurrent bleeding. For both pharmacological and physiological reasons, anti-secretory drugs should be able to reduce rates of recurrent bleeding, given that bleeding sources are acid-related lesions. Because platelet aggregation and plasma coagulation are both abolished while the intra-gastric pH is below 5.4^[30], adequate and sustained acid inhibition results in avoidance of the deleterious effect of acid secretions and pepsin activation on the hemostatic process.

Intravenous PPIs infusion can prevent recurrent bleeding in patients with high risk factors for bleeding peptic ulcers, such as active oozing, non-bleeding visible vessels, and adherent clots^[31,32]. Intravenous omeprazole after endoscopic hemostasis shows better results than either cimetidine or placebo in reducing the rate of recurrent bleeding^[12-14,33,34], the need for endoscopic treatment^[12,13], the number of surgery^[13,34], the need for blood transfusion, and the length of hospitalization^[12].

Empirical therapy with intravenous PPIs should be considered in patients awaiting endoscopy. The use of intravenous PPIs before endoscopy in case of upper gastrointestinal bleeding was shown to accelerate the resolution of signs of bleeding in ulcers^[35], reduce the need for endoscopic therapy and shorten hospital stay^[36]. However, the recurrent bleeding rate, operation rate and mortality rate are similar in patients treated with intravenous PPIs and placebo^[3]. Most recently, Tsoi *et al*^[37] suggested pre-endoscopic administration of PPIs has a lower cost-effectiveness ratio per endoscopic therapy averted (USD \$ 3561) than the placebo (USD \$ 4117). Pre-endoscopic administration of PPIs may be cost-effective in certain situations^[38,39]. Therefore, omeprazole infusion as an adjunct therapy to endoscopic hemostasis in actively bleeding peptic ulcers has a favorable overall clinical outcome.

IV PPIs FOR ULCER RECURRENT BLEEDING CONTROL

Platelet aggregation under different pH conditions

The major defense against hemorrhage is transient vasoconstriction and the subsequent formation of a platelet plug. In an acidic environment, the coagulation cascade and platelet aggregation are inhibited. Green *et al* showed there is a respective 2-fold and 4-fold prolongation of prothrombin time, activated partial thromboplastin time,

and thrombin time at pH 6.4 and pH 6.0 compared to pH 7.4^[30]. More acid conditions result in greater prolongation of these assay times. In an acid milieu, not only the platelet aggregation profile is profoundly inhibited but also disaggregation of stable platelet plugs occurs. The extent of disaggregation is higher at pH 6.1 than at pH 7.3.

Pepsin control of platelet aggregation

Green *et al.* also showed not only the capability of acid to produce alterations in the coagulation cascade, but also the additive effect of pepsin in disaggregating platelets in pH as low as 5.5. At similar pH, the mean total percentage disaggregation is higher in the presence of pepsin than in the absence. In an *in vitro* study, the effect of pepsin on enhancement of platelet disaggregation increases with decreasing pH^[30].

Goal of intragastric pH elevation

The acid environment in the stomach both promotes activation of pepsin and exacerbates gastric mucosal damage. Gastric acid-peptic activity exacerbates superficial mucosal damage into deep ulceration^[40], interferes the ulcer healing^[41], and adversely affects hemostatic mechanisms^[30]. The physiological goal is to achieve an-acidity to arrest hemorrhage in acute gastroduodenal mucosal lesions.

Because platelet aggregation and plasma coagulation are both abolished at pH 5.4 *in vitro*, it is important to achieve intragastric pH higher than pH 5.4 to arrest hemorrhage^[30]. However, endogenous buffers such as hemoglobin in the gut or tissue buffers may be not able to maintain the pH of gastroduodenal contents at or above the level necessary for hemostatic integrity.

Netzer *et al* tested the antisecretory effect of high-dose intravenous omeprazole, delivered either by infusion or injection, over the critical first 72 h. With omeprazole infusion, they found the percentage of time with intragastric pH 6 is 59% on day 1, 71% on day 2 and day 3^[42]. An additional study in India showed that high-dose infusion of PPIs, such as omeprazole, rabeprazole, and pantoprazole achieves an intragastric pH ≥ 6 within 1 h of administration and which is maintained for more than 98% of the time in bleeding peptic ulcers^[43]. Laine *et al* also demonstrated the antisecretory effect of high-dose lansoprazole infusion, which keeps intragastric pH >6 for 67.8% of the time^[44].

The optimal dose of IV PPIs

Current guidelines suggest that patients with bleeding peptic ulcers should be treated with an intravenous omeprazole bolus followed by continuous infusion after endoscopic therapy^[31]. Andersen *et al* evaluated the effect of an initial loading dose of 80 mg omeprazole in intragastric pH and found that it achieves a fast and sustained increase to above pH 4^[45]. Additional studies showed that after an intravenous 80 mg omeprazole bolus, a high-dose continuous infusion, at 8 mg per hour for 72 h, achieves the necessary high intragastric pH-level from the first day to the third day either in healthy subjects^[42] or in patients with bleeding

peptic ulcers^[46]. Four clinical trials suggested therapeutic benefit for high-dose PPIs in reducing recurrent bleeding or in achieving a favorable clinical outcome^[12,13,33,34].

Controversy surrounds the optimal dose required to target intragastric pH and recurrent bleeding control. In Denmark, Kiilerich *et al* showed that low-dose omeprazole at 4 mg/h continuous infusion after a bolus of 80 mg is as effective as the high-dose in maintaining a consistent pH of around 4-6. However, for the low dose omeprazole there is considerable inter-subject variability in AUC and in time with intragastric pH ≥ 4 ^[47]. Nevertheless, although individual intragastric pH response curves are more variable in low-dose omeprazole infusion^[48], Udd *et al* showed a low-dose intravenous bolus of omeprazole of 20 mg daily for 3 d could be still as effective as the high-dose infusion in controlling peptic ulcer recurrent bleeding^[49]. Because of the smaller parietal cells mass^[50] and higher prevalence rate of a poor metabolizer of cytochrome P450 CYP2C19 alleles in Asian populations^[51], it is rational to decrease omeprazole dose in these groups. In Taiwan, Sheu *et al* reported that a decreased dosage of omeprazole with an intravenous 80 mg omeprazole bolus followed with 40 mg bolus twice daily for the consecutive three days could maintain a favorable intragastric pH^[52] and decrease recurrent bleeding^[14]. Another trial in Taiwan also showed that a decreased dosage of omeprazole, 3.3 mg/h infusion or 40 mg injected every 12 h for 3 d could effectively decrease rates of recurrent bleeding^[6,53]. An increase in intravenous dosage to 40 mg per 6 h showed marginally better recurrent bleeding control for Asian populations^[54].

The infusion duration: at least 3 d and longer for some groups

The recurrent bleeding rate of peptic ulcers is related to the presence of the stigmata of recent hemorrhage^[11]. The fading time of non-bleeding visible vessels is around 3 to 6 d^[55]. Commonly, recurrent bleeding may develop within 2-3 d^[56,57]. Accordingly, the common duration of omeprazole infusion is 3 d, applied after the endoscopic therapy^[6,12-14,34,52,58]. Nonetheless, even with continuous infusion of omeprazole for 3 d, recurrent bleeding rates remain high in certain patients such as those with the presence of underlying medical co-morbidities^[1,4,6,10,56]. Clinical trials showed that control of recurrent bleeding following 3-day omeprazole infusion is worse in patients with co-morbidities than in patients without co-morbidities^[6,10]. Moreover, we reported that the duration of peptic ulcer recurrent bleeding is prolonged up to the 14th day after the first bleeding episode in patients with co-morbidities^[6,10]. To prevent recurrent bleeding in such high risk patients, we advocated the therapeutic benefit of a prolonged 7-day course of low-dose intravenous omeprazole which can exert better recurrent bleeding control for up to 1 mo^[59].

Patients with co-morbidities often have a high Rockall risk score ≥ 6 , which indicates that the mean hospital day after acute upper gastro-intestinal hemorrhage should be more than 10 d^[60]. Thus, the cost of the prolonged

admission required for giving a 7-day course of omeprazole infusion is not significant. It should be emphasized that costs associated with a recurrent bleeding event far outweigh costs of PPIs therapy^[61]. The shift to 7-day prolonged low-dose omeprazole treatment does not increase the cost of omeprazole itself, as the amount given is equivalent to 3-day high-dose infusion. Therefore, for such high risk patients, the prolonged duration intravenous PPI should be cost-effective, especially in Asian patients.

Factors related with the poor control of IV PPIs: CYP2C19 story

Several risk factors for recurrent bleeding have been demonstrated in a variety of studies. Inter-patient variability in responsiveness to PPIs therapy may be a factor in failed healing of severe esophagitis^[62], and higher recurrent bleeding rates of peptic ulcers^[63]. One of the reasons maybe because of different metabolizer phenotypes of (*S*)-mephenytoin 4'-hydroxylase (Cytochrome P-450 2C19), by which omeprazole is metabolized to an inactive form^[64,65]. According to the single nucleotide polymorphism and enzyme activity, subjects are divided into extensive metabolizers (EM), intermediate metabolizers, and poor metabolizers (PM). The increasing potency of gastric acid suppression and increasing intragastric pH with oral omeprazole is dependent on the CYP2C19 genotype status in the rank order of homo-EM \leq hetero-EM \leq PM^[66]. There are pronounced geographic and interracial differences in the distribution of this polymorphism. The prevalence rate of PM in Chinese and Japanese is higher than in Caucasians and African descents^[67-73].

In addition to the inter-patient variability in responsiveness to omeprazole therapy, a poor disease background or a poor nutrition status also has negative impact on recurrent bleeding control of peptic ulcers. Patients with two or more co-morbid diseases or with hypoalbuminemia < 3.0 g/dL have a significantly higher risk of recurrent bleeding^[6,10]. Emerging evidence suggests that the incidence of idiopathic peptic ulcers, defined as patients without *H. pylori* infection and no exposure to NSAIDs, is high in the West (between 11% and 44%), and is also increasing in the Asia (from 4.2% to 18.8%)^[74-79]. More than 70% of idiopathic peptic ulcers have comorbid illnesses, half of which are severe or life-threatening systemic disorders, defined as American Society of Anesthesiology score ≥ 3 ^[74,80]. Current evidences indicate that idiopathic peptic ulcers increase the risk of ulcer recurrence and bleeding. Two studies in Hong Kong showed the probability of peptic ulcer recurrence or bleeding in either 12-month or 7-year follow-up is higher in patients with idiopathic peptic ulcers than those with *H. pylori* infection after eradication. One of the two factors associated with recurrent bleeding is comorbidity with severe or life-threatening systemic disorders^[75,80].

The most important systemic disorders are renal failure, liver failure, and disseminated malignancy^[4]. Similarly, a retrospective cohort study found that renal failure and

liver disease are two independent prognostic factors of an unfavorable clinical course, including persistent or recurrent bleeding, required interventional therapy, and death^[81]. Although most recurrent bleeding develops within 72 h^[56,57], uremic patients have a higher delayed recurrent bleeding risk for 7 to 30 d^[10,82].

DIFFERENCES BETWEEN THE ORAL AND IV PPIs

The intragastric 24-h median pH is 4.93 in patients taking oral 40 mg omeprazole once daily, which is significantly higher than baseline median pH of 1.68 in *H. pylori*-negative healthy subjects. However, probably because of diurnal rhythm, the intragastric pH in patients on oral omeprazole falls to a median pH of 3.03 during the night period from 22:00 to 06:00^[83]. Therefore, oral omeprazole 40 mg once daily does not suppress gastric acid secretion completely throughout the 24 h period^[84].

Several studies have shown that oral administration of high-dose PPIs is just as effective in raising the intragastric pH to above 6 and reducing recurrent bleeding as intravenous administration^[43,44,53]. To achieve similar acid control, the dose of oral lansoprazole should be 120 mg bolus then 30 mg per 3 h for 8 times. Results had shown intragastric pH is greater than 6 during 64.8% of the study period, which is similar to 67.8% achieved with intravenous lansoprazole 90 mg bolus injection, followed by 9 mg/h continuous infusion. Therefore, frequent oral PPIs therapy may be able to replace bolus plus constant intravenous PPIs infusion for patients with peptic ulcer bleeding^[44].

LIMITS OF IV PPIs TO CONTROL BLEEDING

As discussed previously, the intravenous bolus and continuous infusion of PPIs following endoscopic therapy is effective in reducing recurrent bleeding in most patients^[6,12-14,34,52,58]. However, not all patients receiving high-dose omeprazole infusion achieve a mean intragastric pH of more than 6. The 30% of patients with high-dose omeprazole infusion who have a mean pH value of less than 6 tend to have a higher recurrent bleeding rate within the first 3 d than those with mean pH values of 6 or greater^[63]. This may reflect inter-patient variability in responsiveness to PPIs therapy^[62,63].

In addition, the presence of co-morbidities and poor nutrition status such as uremia and hypoalbuminemia are also the significant indicators of a higher recurrent bleeding rate even when applying intravenous omeprazole infusion^[6,10,82]. Kamada *et al* found that only one-third of patients with *H. pylori*-negative idiopathic duodenal ulcers may have acid hypersecretion^[85]. Moreover, despite favorable intragastric pH control, patients with comorbid illnesses still have higher recurrent bleeding^[10]. In addition to PPIs, certain host factors should be identified and corrected to prevent recurrent bleeding of peptic ulcers in

such high risk patients^[86].

As described previously, pre-endoscopy administration of PPIs may be cost-effective in certain situations^[38,39]. However, pre-endoscopy administration of PPIs cannot replace urgent endoscopy in managing patients with upper gastrointestinal bleeding^[51].

Because of inter-patient variability in responsiveness to omeprazole therapy^[47,62], there is a need to find a therapy that provides even more effective control of gastric acid secretion and also reduces the variation in acid inhibition between patients. Esomeprazole, the *S*-isomer of omeprazole^[87], has an improved pharmacokinetic profile leading to greater acid suppression than that produced by omeprazole, pantoprazole, lansoprazole, and rabeprazole^[88]. Because the metabolism of omeprazole is stereoselective, the sum of the intrinsic clearance values is 3 times lower for *S*-omeprazole than for *R*-omeprazole^[89-91]. Following an intravenous bolus of 80 mg and then 8 mg/h continuous infusion, the AUCt and Cmax of esomeprazole is higher than that of omeprazole^[92]. The inter-subject variability of esomeprazole for AUCt is also significantly lower and time with intragastric pH > 4 is less than with omeprazole. Although similar acid suppression achieved by i.v. esomeprazole and i.v. omeprazole, the former has a tendency for a faster onset of action (2 h shorter to the target pH > 6) and significantly lower variability in pharmacodynamic response than the later^[92]. Moreover, the median intragastric pH of esomeprazole 40 mg i.v. is significantly higher than that of pantoprazole 40 mg i.v. infusion and bolus injection^[93]. The duration to achieve elevation of pH > 4 is longer in the former than in the later (1.7 h *vs.* 0.6 h, *P* < 0.0001)^[94].

In clinical studies, the greater acid suppression produced by esomeprazole has been translated into higher healing rates and more effective symptom relief when compared to other PPIs in patients with gastro-esophageal reflux disease^[95-98]. In a multiethnic study, Sung *et al* showed the high-dose intravenous esomeprazole infusion given after successful endoscopic therapy to patients with high-risk peptic ulcer bleeding has a lower recurrent bleeding rate and a better clinical outcomes than placebo^[99]. Therefore, because the variability in the pharmacodynamic response of intravenous esomeprazole is lower, intravenous esomeprazole could be applied in different CYP2C19 genotypes in preventing recurrent bleeding. However, clinical benefits of intravenous esomeprazole for high risk patients such as those with co-morbidities should be further investigated.

CONCLUSION

In summary, an intravenous omeprazole bolus followed by high-dose continuous infusion for 72 h after successful endoscopic therapy has been shown to inhibit gastric acid secretion effectively and have clinical benefits on the prevention of recurrent bleeding in most patients. In the Asian, low-dose omeprazole infusion can effectively decrease rates of recurrent bleeding. Nevertheless, patients with co-morbidities such as renal failure, liver disease, and hypoalbuminemia or who are extensive metabolizers of

CYP2C19 genotype may experience higher rates of recurrent bleeding. The prolonged 7-day course of low-dose intravenous omeprazole may decrease recurrent bleeding in such patients with medical comorbidities. There is a need to validate whether intravenous esomeprazole can improve the control of peptic ulcer recurrent bleeding, especially for patients with different CYP2C19 genotypes and with underlying comorbidities.

REFERENCES

- 1 **Yavorski RT**, Wong RK, Maydonovitch C, Battin LS, Furnia A, Amundson DE. Analysis of 3,294 cases of upper gastrointestinal bleeding in military medical facilities. *Am J Gastroenterol* 1995; **90**: 568-573
- 2 **Longstreth GF**. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. *Am J Gastroenterol* 1995; **90**: 206-210
- 3 **Silverstein FE**, Gilbert DA, Tedesco FJ, Buenger NK, Persing J. The national ASGE survey on upper gastrointestinal bleeding. I. Study design and baseline data. *Gastrointest Endosc* 1981; **27**: 73-79
- 4 **Rockall TA**, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. *Gut* 1996; **38**: 316-321
- 5 **Katschinski B**, Logan R, Davies J, Faulkner G, Pearson J, Langman M. Prognostic factors in upper gastrointestinal bleeding. *Dig Dis Sci* 1994; **39**: 706-712
- 6 **Cheng HC**, Chuang SA, Kao YH, Kao AW, Chuang CH, Sheu BS. Increased risk of rebleeding of peptic ulcer bleeding in patients with comorbid illness receiving omeprazole infusion. *Hepatogastroenterology* 2003; **50**: 2270-2273
- 7 **Forrest JAN**, Finlayson NDC, Sherman DJC. Endoscopy in gastrointestinal bleeding. *Lancet* 1974; **2**: 394-397
- 8 **Lim CH**, Vani D, Shah SG, Everett SM, Rembacken BJ. The outcome of suspected upper gastrointestinal bleeding with 24-hour access to upper gastrointestinal endoscopy: a prospective cohort study. *Endoscopy* 2006; **38**: 581-585
- 9 **Terdiman JP**, Ostroff JW. Gastrointestinal bleeding in the hospitalized patient: a case-control study to assess risk factors, causes, and outcome. *Am J Med* 1998; **104**: 349-354
- 10 **Cheng HC**, Kao AW, Chuang CH, Sheu BS. The efficacy of high- and low-dose intravenous omeprazole in preventing rebleeding for patients with bleeding peptic ulcers and comorbid illnesses. *Dig Dis Sci* 2005; **50**: 1194-1120
- 11 **Johnston JH**. Endoscopic risk factors for bleeding peptic ulcer. *Gastrointest Endosc* 1990; **36**: S16-S20
- 12 **Lau JY**, Sung JJ, Lee KK, Yung MY, Wong SK, Wu JC, Chan FK, Ng EK, You JH, Lee CW, Chan AC, Chung SC. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. *N Engl J Med* 2000; **B**: 310-316
- 13 **Schaffalitzky de Muckadell OB**, Havelund T, Harling H, Boesby S, Snel P, Vreeburg EM, Eriksson S, Fernström P, Hasselgren G. Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers. Randomized double-blind placebo-controlled multicentre study. *Scand J Gastroenterol* 1997; **32**: 320-327
- 14 **Sheu BS**, Chi CH, Huang CC, Kao AW, Wang YL, Yang HB. Impact of intravenous omeprazole on Helicobacter pylori eradication by triple therapy in patients with peptic ulcer bleeding. *Aliment Pharmacol Ther* 2002; **16**: 137-143
- 15 **Freston JW**. Overview of medical therapy of peptic ulcer disease. *Gastroenterol Clin North Am* 1990; **19**: 121-140
- 16 **Shin JM**, Besancon M, Bamberg K, Sachs G. Structural aspects of the gastric H,K ATPase. *Ann N Y Acad Sci* 1997; **834**: 65-76
- 17 **Sachs G**. The gastric H, K ATPase. In: Johnson LR. Physiology of the gastrointestinal tract. 3rd ed. New York: Raven

- Press, 1994; 1119-1138
- 18 **Yao X**, Forte JG. Cell biology of acid secretion by the parietal cell. *Annu Rev Physiol* 2003; **65**: 103-131
 - 19 **Sachs G**. The parietal cell as a therapeutic target. *Scand J Gastroenterol* 1986; **118 Suppl**: 1-10
 - 20 **Sachs G**, Carlsson E, Lindberg P, Wallmark B. Gastric H, K-ATPase as therapeutic target. *Annu Rev Pharmacol Toxicol* 1988; **28**: 269-284
 - 21 **Fellenius E**, Berglinth T, Sachs G, Olbe L, Elander B, Sjöstrand SE, Wallmark B. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H⁺ + K⁺)ATPase. *Nature* 1981; **290**: 159-161
 - 22 **Wallmark B**. Omeprazole: mode of action and effect on acid secretion in animals. *Scand J Gastroenterol* 1989; **166 Suppl**: 12-18
 - 23 **Clissold SP**, Campoli-Richards DM. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. *Drugs* 1986; **32**: 15-47
 - 24 **Walan A**, Bader JP, Classen M, Lamers CB, Piper DW, Rutgersson K, Eriksson S. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. *N Engl J Med* 1989; **320**: 69-75
 - 25 **Lindberg P**, Brandstrom A, Wallmark B, Mattsson H, Rikner L, Hoffmann KJ. Omeprazole: the first proton pump inhibitor. *Med Res Rev* 1990; **10**: 1-54
 - 26 **Lindberg P**, Nordberg P, Alminger T, Brandstrom A, Wallmark B. The mechanism of action of the gastric acid secretion inhibitor omeprazole. *J Med Chem* 1986; **29**: 1327-1329
 - 27 **Lorentzon P**, Jackson R, Wallmark B, Sachs G. Inhibition of (H⁺ + K⁺)-ATPase by omeprazole in isolated gastric vesicles requires proton transport. *Biochim Biophys Acta* 1987; **897**: 41-51
 - 28 **Maton PN**. Omeprazole. *N Engl J Med* 1991; **324**: 965-975
 - 29 **Kaunitz JD**, Sachs G. Identification of a vanadate-sensitive potassium-dependent proton pump from rabbit colon. *J Biol Chem* 1986; **261**: 14005-14010
 - 30 **Green FW Jr**, Kaplan MM, Curtis LE, Levine PH. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. *Gastroenterology* 1978; **74**: 38-43
 - 31 **Barkun A**, Bardou M, Marshall JK. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. *Ann Intern Med* 2003; **139**: 843-857
 - 32 **Sung JJ**, Chan FK, Lau JY, Yung MY, Leung WK, Wu JC, Ng EK, Chung SC. The effect of endoscopic therapy in patients receiving omeprazole for bleeding ulcers with nonbleeding visible vessels or adherent clots: a randomized comparison. *Ann Intern Med* 2003; **139**: 237-243
 - 33 **Lin HJ**, Lo WC, Lee FY, Perng CL, Tseng GY. A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. *Arch Intern Med* 1998; **158**: 54-58
 - 34 **Hasselgren G**, Lind T, Lundell L, Aadland E, Efskind P, Falk A, Hyltander A, Söderlund C, Eriksson S, Fernström P. Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding. Results of a placebo-controlled multicenter study. *Scand J Gastroenterol* 1997; **32**: 328-333
 - 35 **Daneshmend TK**, Hawkey CJ, Langman MJ, Logan RF, Long RG, Walt RP. Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled trial. *BMJ* 1992; **304**: 143-147
 - 36 **Lau JY**, Leung WK, Wu JC, Chan FK, Wong VW, Chiu PW, Lee VW, Lee KK, Cheung FK, Siu P, Ng EK, Sung JJ. Omeprazole before endoscopy in patients with gastrointestinal bleeding. *N Engl J Med* 2007; **356**: 1631-1640
 - 37 **Tsoi KK**, Lau JY, Sung JJ. Cost-effectiveness analysis of high-dose omeprazole infusion before endoscopy for patients with upper-GI bleeding. *Gastrointest Endosc* 2008; **67**: 1056-1063
 - 38 **Barkun A**, Kennedy W, Herba K, Fallone C. The cost effectiveness of proton pump inhibitor continuous infusion (IV PPI) administered prior to endoscopy in the treatment of patients with non-variceal upper GI bleeding. The RUGBE. *Gastroenterology* 2002; **122**: A67.
 - 39 **Enns RA**, Gagnon YM, Rioux KP, Levy AR. Cost-effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding. *Aliment Pharmacol Ther* 2003; **17**: 225-233
 - 40 **Wallace JL**, McKnight GW. Themucoid cap over superficial gastric damage in the rat. A high-pH microenvironment dissipated by nonsteroidal antiinflammatory drugs and endothelin. *Gastroenterology* 1990; **99**: 295-304
 - 41 **Schmassmann A**, Tarnawski A, Peskar BM, Varga L, Flogerzi B, Halter F. Influence of acid and angiogenesis on kinetics of gastric ulcer healing in rats: interaction with indomethacin. *Am J Physiol* 1995; **268**: G276-G285
 - 42 **Netzer P**, Gaia C, Sandoz M, Huluk T, Gut A, Halter F, Husler J, Inauen W. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. *Am J Gastroenterol* 1999; **94**: 351-357
 - 43 **Javid G**, Zargar SA, U-Saif R, Khan BA, Yattoo GN, Shah AH, Gulzar GM, Sodhi JS, Khan MA. Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer. *J Gastroenterol Hepatol* 2009; **24**: 1236-1243
 - 44 **Laine L**, Shah A, Bemanian S. Intragastric pH with oral vs intravenous bolus plus infusion proton-pump inhibitor therapy in patients with bleeding ulcers. *Gastroenterology* 2008; **134**: 1836-1841
 - 45 **Andersen J**, Ström M, Naesdal J, Leire K, Walan A. Intravenous omeprazole: effect of a loading dose on 24-h intragastric pH. *Aliment Pharmacol Ther* 1990; **4**: 65-72
 - 46 **Labenz J**, Peitz U, Leusing C, Tillenburg B, Blum AL, Börsch G. Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study. *Gut* 1997; **40**: 36-41
 - 47 **Latterre PF**, Horsmans Y. Intravenous omeprazole in critically ill patients: a randomized, crossover study comparing 40 with 80 mg plus 8 mg/hour on intragastric pH. *Crit Care Med* 2001; **29**: 1931-1935
 - 48 **Kiilerich S**, Rannem T, Elsborg L. Effect of intravenous infusion of omeprazole and ranitidine on twenty-four-hour intragastric pH in patients with a history of duodenal ulcer. *Digestion* 1995; **56**: 25-30
 - 49 **Udd M**, Miettinen P, Palmu A, Heikkinen M, Janatuinen E, Pasanen P, Tarvainen R, Kairaluoma MV, Lohman M, Mustonen H, Julkunen R. Regular-dose versus high-dose omeprazole in peptic ulcer bleeding: a prospective randomized double-blind study. *Scand J Gastroenterol* 2001; **36**: 1332-1338
 - 50 **Lam SK**, Hasan M, Sircus W, Wong J, Ong GB, Prescott RJ. Comparison of maximal acid output and gastrin response to meals in Chinese and Scottish normal and duodenal ulcer subjects. *Gut* 1980; **21**: 324-328
 - 51 **Bertilsson L**. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. *Clin Pharmacokinet* 1995; **29**: 192-209
 - 52 **Sheu BS**, Chi CH, Yang HB, Jen CM, Lin XZ. A three-day course of intravenous omeprazole plus antibiotics for H. pylori-positive bleeding duodenal ulcer. *Hepatogastroenterology* 1999; **46**: 2363-2371
 - 53 **Tsai JJ**, Hsu YC, Perng CL, Lin HJ. Oral or intravenous proton pump inhibitor in patients with peptic ulcer bleeding after successful endoscopic epinephrine injection. *Br J Clin Pharmacol* 2009; **67**: 326-332
 - 54 **Lin HJ**, Lo WC, Cheng YC, Perng CL. Role of intravenous omeprazole in patients with high-risk peptic ulcer bleeding after successful endoscopic epinephrine injection: a prospective randomized comparative trial. *Am J Gastroenterol* 2006; **101**: 500-505
 - 55 **Yang CC**, Shin JS, Lin XZ, Hsu PI, Chen KW, Lin CY. The natural history (fading time) of stigmata of recent hemorrhage

- hage in peptic ulcer disease. *Gastrointest Endosc* 1994; **40**: 562-566
- 56 **de Dombal FT**, Clarke JR, Clamp SE, Malizia G, Kotwal MR, Morgan AG. Prognostic factors in upper G.I. bleeding. *Endoscopy* 1986; **18 Suppl 2**: 6-10
- 57 **Lin HJ**, Perng CL, Lee YL, Lee CH, Lee SD. Clinical courses and predictors for rebleeding in patients with peptic ulcers and non-bleeding visible vessels: a prospective study. *Gut* 1994; **35**: 1389-1393
- 58 **Goletti O**, Sidoti F, Lippolis PV, De Negri F, Cavina E. Omeprazole versus ranitidine plus somatostatin in the treatment of severe gastroduodenal bleeding: a prospective, randomized, controlled trial. *Ital J Gastroenterol* 1994; **26**: 72-74
- 59 **Cheng HC**, Chang WL, Yeh YC, Chen WY, Tsai YC, Sheu BS. Seven-day intravenous low-dose omeprazole infusion reduces peptic ulcer rebleeding for patients with comorbidities. *Gastrointest Endosc* 2009; **70**: 433-439
- 60 **Lin HJ**, Perng CL, Lee FY, Lee CH, Lee SD. Clinical courses and predictors for rebleeding in patients with peptic ulcers and non-bleeding visible vessels: a prospective study. *Gut* 1994; **35**: 1389-1393
- 61 **Devlin JW**, Welage LS. The cost-effectiveness of proton pump inhibitors for bleeding peptic ulcers: The unanswered questions. *Crit Care Med* 2004; **32**: 1415-1416
- 62 **Holloway RH**, Dent J, Narielvala F, Mackinnon AM. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. *Gut* 1996; **38**: 649-654
- 63 **Hsieh YH**, Lin HJ, Tseng GY, Perng CL, Wang K, Lo WC, Chang FY, Lee SD. Poor responders to intravenous omeprazole in patients with peptic ulcer bleeding. *Hepatogastroenterology* 2004; **51**: 316-319
- 64 **Jensen JC**, Gugler R. Inhibition of human liver cytochrome P-450 by omeprazole. *Br J Clin Pharmacol* 1986; **21**: 328-330
- 65 **Diaz D**, Fabre I, Daujat M, Saint Aubert B, Bories P, Michel H, Maurel P. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. *Gastroenterology* 1990; **99**: 737-747
- 66 **Shimatani T**, Inoue M, Kuroiwa T, Horikawa Y, Mieno H, Nakamura M. Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and famotidine 20 mg, a new H₂-receptor antagonist. *Aliment Pharmacol Ther* 2003; **18**: 1149-1157
- 67 **Wedlund PJ**, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. *Clin Pharmacol Ther* 1984; **36**: 773-780
- 68 **Nakamura K**, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. *Clin Pharmacol Ther* 1985; **38**: 402-408
- 69 **Xie HG**, Kim RB, Stein CM, Wilkinson GR, Wood AJ. Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent. *Br J Clin Pharmacol* 1999; **48**: 402-408
- 70 **Xie HG**, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. *Pharmacogenetics* 1999; **9**: 539-549
- 71 **Xie HG**. Genetic variations of S-mephenytoin 4'-hydroxylase (CYP2C19) in the Chinese population. *Life Sci* 2000; **66**: PL175-PL181
- 72 **Sheu BS**, Kao AW, Cheng HC, Hunag SF, Chen TW, Lu CC, Wu JJ. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. *Aliment Pharmacol Ther* 2005; **21**: 283-288
- 73 **Tseng PH**, Lee YC, Chiu HM, Wang HP, Lin JT, Wu MS. A comparative study of proton-pump inhibitor tests for Chinese reflux patients in relation to the CYP2C19 genotypes. *J Clin Gastroenterol* 2009; **43**: 920-925
- 74 **Chan HL**, Wu JC, Chan FK, Choi CL, Ching JY, Lee YT, Leung WK, Lau JY, Chung SC, Sung JJ. Is non-Helicobacter pylori, non-NSAID peptic ulcer a common cause of upper GI bleeding? A prospective study of 977 patients. *Gastrointest Endosc* 2001; **53**: 438-442
- 75 **Hung LC**, Ching JY, Sung JJ, To KF, Hui AJ, Wong VW, Leong RW, Chan HL, Wu JC, Leung WK, Lee YT, Chung SC, Chan FK. Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study. *Gastroenterology* 2005; **128**: 1845-1850
- 76 **Kurata JH**, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. *J Clin Gastroenterol* 1997; **24**: 2-17
- 77 **Jyotheeswaran S**, Shah AN, Jin HO, Potter GD, Ona FV, Chey WY. Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified? *Am J Gastroenterol* 1998; **93**: 574-578
- 78 **Sprung DJ**, Apter MN. What is the role of Helicobacter pylori in peptic ulcer and gastric cancer outside the big cities? *J Clin Gastroenterol* 1998; **26**: 60-63
- 79 **Schubert M**, McGuire VAMC, Dewitt JM, Taylor CA. Prospective evaluation of the prevalence of H. pylori in duodenal and gastric ulcer: is its role overstated? *Gastroenterology* 1999; **116**: A305
- 80 **Wong GL**, Wong VW, Chan Y, Ching JY, Au K, Hui AJ, Lai LH, Chow DK, Siu DK, Lui YN, Wu JC, To KF, Hung LC, Chan HL, Sung JJ, Chan FK. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. *Gastroenterology* 2009; **137**: 525-531
- 81 **Zaragoza AM**, Tenias JM, Llorente MJ, Alborch A. Prognostic factors in gastrointestinal bleeding due to peptic ulcer: construction of a predictive model. *J Clin Gastroenterol* 2008; **42**: 786-790
- 82 **Tseng GY**, Fang CT, Lin HJ, Yang HB, Tseng GC, Wang PC, Liao PC, Cheng YT, Huang CH. Efficacy of an intravenous proton pump inhibitor after endoscopic therapy with epinephrine injection for peptic ulcer bleeding in patients with uraemia: a case-control study. *Aliment Pharmacol Ther* 2009; **30**: 406-413
- 83 **Moore JG**, Englert E Jr. Circadian rhythm of gastric acid secretion in man. *Nature* 1970; **226**: 1261-1262
- 84 **Gan KH**, Geus WP, Lamers CB, Heijerman HG. Effect of omeprazole 40 mg once daily on intraduodenal and intragastric pH in H. pylori-negative healthy subjects. *Dig Dis Sci* 1997; **42**: 2304-2309
- 85 **Kamada T**, Haruma K, Kusunoki H, Miyamoto M, Ito M, Kitadai Y, Yoshihara M, Chayama K, Tahara K, Kawamura Y. Significance of an exaggerated meal-stimulated gastrin response in pathogenesis of Helicobacter pylori-negative duodenal ulcer. *Dig Dis Sci* 2003; **48**: 644-651
- 86 **Cheng HC**, Yang HB, Chang WL, Yeh YC, Chen WC, Tsai YC, Sheu BS. Lacking of up-regulation of serum response factor on gastric ulcer correlates to persistence of stigmata of recent hemorrhage and rebleeding. *J Gastroenterol Hepatol* 2009; **24 Suppl 1**: A26
- 87 **Carlsson E**, Lindberg P, von Unge S. Two of a kind. *Chem Br* 2002; **38**: 42-45
- 88 **Spencer CM**, Faulds D. Esomeprazole. *Drugs* 2000; **60**: 321-329; discussion 330-331
- 89 **Åbelö A**, Andersson TB, Antonsson M, Naudot AK, Skånberg I, Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. *Drug Metab Dispos* 2000; **28**: 966-972
- 90 **Andersson T**, Bredberg E, Sunzel M, Madeleine A, Weidolf L, AstraZeneca LP, Wayne PA; AstraZeneca R&D. Pharmacokinetics (PK) and effect on pentagastrin stimulated peak acid output (PAO) of omeprazole (O) and its 2 optical isomers, S-omeprazole/esomeprazole (E) and R-omeprazole (R-O). *Gastroenterology* 2000; **118 (4 Pt II)**: A1210
- 91 **Andersson T**, Hassan-Alin M, Hasselgren G, Röhss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. *Clin Pharmacokinet* 2001; **40**: 411-426

- 92 **Röhss K**, Wilder-Smith C, Kilhamn J, Fjellman M, Lind T. Suppression of gastric acid with intravenous esomeprazole and omeprazole: results of 3 studies in healthy subjects. *Int J Clin Pharmacol Ther* 2007; **45**: 345-354
- 93 **Hartmann D**, Eickhoff A, Damian U, Riemann JF, Schilling D. Effect of intravenous application of esomeprazole 40 mg versus pantoprazole 40 mg on 24-hour intragastric pH in healthy adults. *Eur J Gastroenterol Hepatol* 2007; **19**: 133-137
- 94 **Wilder-Smith CH**, Röhss K, Bondarov P, Hallerbäck B, Svedberg LE, Ahlbom H. Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study. *Aliment Pharmacol Ther* 2004; **20**: 1099-1104
- 95 **Kahrilas PJ**, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, D'Amico D, Hamelin B, Joelsson B. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. *Aliment Pharmacol Ther* 2000; **14**: 1249-1258
- 96 **Castell DO**, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S, Skammer W, Levine JG. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. *Am J Gastroenterol* 2002; **97**: 575-583
- 97 **Richter JE**, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, Marino V, Hamelin B, Levine JG. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. *Am J Gastroenterol* 2001; **96**: 656-665
- 98 **Labenz J**, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schütze K, Wallner G, Juergens H, Preiksaitis H, Keeling N, Naucler E, Eklund S. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. *Aliment Pharmacol Ther* 2005; **21**: 739-746
- 99 **Sung JJ**, Barkun A, Kuipers EJ, Mössner J, Jensen DM, Stuart R, Lau JY, Ahlbom H, Kilhamn J, Lind T. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. *Ann Intern Med* 2009; **150**: 455-464

S- Editor Zhang HN L- Editor Hughes D E- Editor Zhang L

Endoscopic and anesthetic feasibility of EUS and ERCP combined in a single session versus two different sessions

Juan J Vila, Marcos Kutz, Silvia Goñi, Miriam Ostiz, Edurne Amorena, Carlos Prieto, Cristina Rodriguez, Ignacio Fernández-Urien, Francisco J Jiménez

Juan J Vila, Marcos Kutz, Silvia Goñi, Miriam Ostiz, Edurne Amorena, Carlos Prieto, Cristina Rodriguez, Ignacio Fernández-Urien, Francisco J Jiménez, Endoscopy Unit, Gastroenterology Department, Complejo Hospitalario de Navarra, Pamplona 31008, Spain

Author contributions: Vila JJ was responsible for the study design, manuscript draft and coordination; Kutz M was responsible for writing corrections and data collection; Ostiz M and Amorena E were responsible for data collection; Prieto C and Rodríguez C performed statistical analysis and interpretation; Fernández-Urien I provided a critical review; and Jiménez FJ gave the final approval.

Correspondence to: Juan J Vila, MD, Endoscopy Unit, Gastroenterology Department, Centro Hospitalario de Navarra, Pamplona 31008, Spain. juanjvila@gmail.com

Telephone: +34-848-422114 Fax: +34-848-422303

Received: November 08, 2010 Revised: February 16, 2011

Accepted: February 23, 2011

Published online: March 16, 2011

Abstract

AIM: To discuss the feasibility of single session endoscopic ultrasonography (EUS) to discuss and endoscopic retrograde cholangiopancreatography (ERCP) execution.

METHODS: Retrospective endoscopic and anesthetic outcome comparison of performing both EUS and ERCP in a single endoscopic session (Group I) versus performing each procedure in two different sessions (Group II) was made. The following variables were evaluated: epidemiological variables, American Society of Anesthesiologists Physical Status Classification (ASA) level, procedural time, propofol dose, anesthetic complications, endoscopic complications and diagnostic yield, and therapeutic procedures on both groups. T-student, Chi-Square and Fisher test were used for comparison.

RESULTS: We included 39 patients in Group I (mean

age: 69.85 ± 9.25 ; 27 men) and 46 in Group II (mean age: 67.46 ± 12.57 ; 25 men). Procedural time did not differ significantly between both groups (Group I vs Group II: 93 ± 32.78 vs 98.98 ± 38.17 ; $P > 0.05$) but the dose of propofol differed (Group I vs Group II: 322.28 ± 250.54 mg vs 516.96 ± 289.06 mg; $P = 0.001$). Three patients had normal findings on both explorations. Three anesthetic complications [O_2 desaturation (2), broncoaspiration (1)] and 9 endoscopic complications [pancreatitis (6), bleeding (1), perforation (1), cholangitis (1)] occurred without significant differences between both groups ($P > 0.05$). We did not find any significant difference regarding age, sex, ASA scale level, diagnostic yield or therapeutic maneuvers between both groups.

CONCLUSION: The performance of EUS and ERCP in a single session offers a similar diagnostic and therapeutic yield, does not entail a higher complication risk and requires a significantly smaller dose of propofol for sedation compared with performing each exploration in a different session.

© 2011 Baishideng. All rights reserved.

Key words: Endosonography; Endoscopic Retrograde Cholangiopancreatography; Feasibility Studies; Endoscopy; Gastrointestinal; Anesthesia

Peer reviewer: Perminder Phull, MD, FRCP, FRCPE, Gastrointestinal and Liver Service, Room 2.58, Ashgrove House, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN, United Kingdom

Vila JJ, Kutz M, Goñi S, Ostiz M, Amorena E, Prieto C, Rodríguez C, Fernández-Urien I, Jiménez FJ. Endoscopic and anesthetic feasibility of EUS and ERCP combined on a single session versus two different sessions. *World J Gastrointest Endosc* 2011; 3(3): 57-61 Available from: URL: <http://www.wjgnet.com/1948-5190/full/v3/i3/57.htm> DOI: <http://dx.doi.org/10.4253/wjge.v3.i3.57>

INTRODUCTION

Endoscopic ultrasonography (EUS) and endoscopic retrograde cholangio-pancreatography (ERCP) have become two essential diagnostic and therapeutic tools in patients with biliary and pancreatic diseases. Performing both procedures in a single anesthetic and endoscopic session has theoretical advantages, as reported by some authors^[1]. But this tandem approach is currently a topic of debate and is discouraged by other authors based on the observation of complications seen after performing EUS with fine needle aspiration (EUS-FNA) followed by ERCP^[2,3]. Development of cardiac complications has also been described in relation with prolonged ERCP procedures^[4].

Despite encouraging results referring to feasibility of tandem procedures described in some series^[5,6], comparative studies are lacking, so controversy still remains and this issue should be further clarified. Thus, the aim of this study was to compare the feasibility, clinical, endoscopic and anesthetic outcomes of performing EUS and ERCP in a single session versus performing each procedure in a different session. Although retrospective, this is the first comparative study to our knowledge reported in the literature regarding this topic.

MATERIAL AND METHODS

We compared the outcomes of a group of consecutive patients who underwent EUS and ERCP in a single session (Group I) versus a group of consecutive patients who underwent EUS and ERCP in two different sessions (Group II) from January 2006 until May 2009. Data were collected retrospectively from a review of the electronic medical record and endoscopy database from our hospital. Patients included in Group II underwent EUS and ERCP as part of the diagnostic and therapeutic work-up for the same disease. The decision to perform both explorations on the same day or on two different days was made by the referring clinician.

In Group I, both explorations were performed in a fluoroscopy suite specifically dedicated to this type of intervention during the same sedation procedure. In Group II, EUS was performed in an endoscopy unit lounge without fluoroscopy equipment and ERCP was performed some days later in the same suite as Group I. All the explorations were performed under sedation with propofol, administered by an anesthetic team comprised of an anesthesiologist and a nurse. To reduce duodenal motility during ERCP, intravenous hyoscine butylbromide was given following the anesthesiologist's criteria.

EUS was accomplished first in all patients, followed by ERCP. EUS explorations were performed by two endoscopists and ERCP by three endoscopists, assisted on both explorations by a nurse. EUS was done using a radial echoendoscope (Pentax EG3630UR, Pentax Europe, Hamburg, Germany) with evaluation of the entire pancreas, ampulla, extrahepatic bile duct, liver, retroperitoneal space and posterior mediastinum. When a pancreatic mass, liver metastasis or distant lymph nodes

in patients with oncological disease were seen, FNA was performed with a linear array echoendoscope (Pentax EG3830UT, Pentax Europe, Hamburg, Germany) using a 22 G needle (Echo-Tip, Wilson-Cook medical, Inc., Winston-Salem, NC, USA). When a thickened extrahepatic bile duct was found, brush cytology or biopsy was obtained during ERCP following our team's policy. ERCP was performed using a lateral view duodenoscope with therapeutic channel (Olympus TJF160VR, Olympus Medical Systems Corp, Tokyo, Japan). When EUS-FNA was performed, the specimens were immediately assessed on-site for adequacy by a dedicated cytopathologist.

The following variables were recorded: age, gender, American Society of Anesthesiologists Physical Status Classification (ASA), procedural time, administered propofol dose, cardiopulmonary complications, endoscopic complications and diagnostic yield of both explorations. The procedural time was considered from the moment that cardiopulmonary monitorization was initiated before sedation to the moment the patient left the exploration room. In Group II, the procedural time and total propofol dose were calculated by adding the values of each individual exploration. All ERCPs were performed on an in-patient basis, observing the patient for at least 24 h after ERCP before discharge.

Statistical analysis

Quantitative variables are presented as mean value \pm standard deviation. T-student test was used for the comparison of quantitative variables and Fisher exact test was used for the comparison of qualitative variables. The normal distribution of quantitative variables was evaluated with the Kolgomorov-Smirnoff Z test. Statistical significance was considered for *P* values under 0.05.

RESULTS

A total of 39 patients were included in Group I with a mean age of 69.85 ± 9.25 years. Twenty-seven of these patients were men. On the other hand, 46 patients were included in Group II. This group mean age was 67.46 ± 12.57 years and 25 were men. The indication for endoscopic study was suspected choledocolithiasis in 9 patients (11%), pancreatic cancer in 18 patients (21%), ampulloma in 5 patients (6%), cholangiocarcinoma in 4 patients (5%), chronic pancreatitis in 3 patients (3%), pancreatic pseudocyst in 1 patient (1%) and suspected pancreatobiliary disease without definitive diagnosis prior to endoscopic explorations in 45 patients (53%). Seventy three patients (86%) were studied with transabdominal ultrasonography prior to the endoscopic procedure, 61 (72%) with a CT and 25 (30%) with magnetic resonance cholangiopancreatography. No significant differences regarding age, sex and indication of endoscopy were seen between both groups.

ASA scale distribution of patients is shown in Table 1. When we analyzed patients regrouped as low ASA grade (including patients with ASA I and II) and high

Table 1 ASA Physical Status Classification distribution of patients in Group I and Group II

American Society of Anesthesiologists (ASA) Physical Status Classification				
	I	II	III	IV
Group I	3	19	15	2
Group II	4	17	23	2

ASA: American Society of Anesthesiologists

ASA grade (ASA III and higher), no differences between both groups were found, with 21 patients with a low ASA grade in Group I and 22 patients in Group II.

During ERCP, brush cytology was obtained in 20 patients (23%), retrieving an adequate specimen in 14 of them (diagnostic yield of 70%). Nine of these patients were included in Group I and 11 in Group II. Forceps biopsy was taken in 15 patients, 4 from Group I and 11 from Group II. The histological study was diagnostic in all of them. Eight of these patients had an ampullary tumor. EUS-PAAF was required in 19 patients in Group I and 13 in Group II, resulting in a correct specimen extraction in 17 patients in Group I and 12 patients in Group II. No significant differences were seen regarding the distribution or the diagnostic yield of EUS-FNA, brush cytology or forceps biopsy between both groups ($P > 0.05$).

Mean procedural time was 93 ± 32.78 min in Group I and 98.98 ± 38.17 min in Group II, without significant differences between them. Regarding the amount of administered propofol, patients included in Group I received a mean dose of 322.28 ± 250.54 mg while the dose administered to patients included in Group II was 516.96 ± 289.06 mg, significantly higher ($P = 0.002$). Age, procedural time and propofol dose variables followed a normal distribution.

Three patients in Group I suffered desaturation during the tandem exploration. Two episodes resolved after increasing inhaled oxygen flow and jaw thrust and the other required oro-tracheal intubation. One of the former was later diagnosed with aspiration pneumonia and had an uneventful recovery. Only one patient in Group II suffered desaturation which resolved with jaw thrust and oro-pharyngeal cannulation. No other cardiopulmonary complications were seen. None of these complications prevented our team from completing the endoscopic procedure.

Endoscopic complications appeared in 9 patients (11%), all of them related to ERCP. In Group I, one patient developed post-ERCP pancreatitis and another suffered sphincterotomy bleeding requiring endoscopic therapy. In Group II, five patients developed post-ERCP pancreatitis, one developed post-ERCP cholangitis and one suffered a retroperitoneal perforation. This latter patient developed a retroperitoneal abscess and required percutaneous drainage. The rest of the patients had an uneventful recovery with conservative management.

No significant differences between both groups were seen with regard to presentation of cardiopulmonary or

Table 2 Therapeutic maneuvers performed on Group I and II

		Group I	Group II	P
Sphincterotomy	Yes	17	22	0.69
	No	22	24	
Common bile duct stone extraction	Yes	9	5	0.13
	No	30	41	
Biliary plastic stent	Yes	14	24	0.18
	No	25	22	
Biliary metallic stent	Yes	6	3	0.29
	No	33	43	
Pancreatic plastic stent	Yes	0	3	0.24
	No	39	43	
Endoscopic therapy	Not Necessary	8	1	0.006
	Necessary	31	45	

endoscopic complications ($P > 0.05$).

Final diagnosis after both explorations was pancreatic cancer in 30 patients, cholangiocarcinoma in 9, ampulloma in 8, choledocolithiasis in 23, chronic pancreatitis in 7 and other findings in 3 patients. Three patients had normal findings on both explorations. No significant differences between Group I and II were observed regarding the final diagnostic yield.

Patients who did not undergo any therapeutic procedures were more common on Group I ($P < 0.05$). No other therapeutic differences were seen between both groups (Table 2).

DISCUSSION

EUS and ERCP are currently two complementary techniques in the diagnosis and therapeutic work-up of patients with pancreatic and biliary diseases. Performing both explorations in the same session is an appealing policy which is in common use in some tertiary centers and is supported by published data and expert opinion^[1,5,6]. This policy has important advantages for endoscopists as has been previously stated^[1]. These advantages include performing EUS in naïve conditions which might be important in pancreatic and biliary cancer staging^[7,8]. Only one sedation procedure would be necessary for the same patient and this, in the opinion of some authors, could reduce the demand on anesthetic resources^[5]. Performing EUS initially could guide the biliary or pancreatic access and therapy on ERCP since the endoscopist gets useful clinical and anatomical information. Cost-effectiveness could be another advantage of the tandem approach since the procedure time and endoscopic and anaesthetic resources could be lowered. To these theoretical advantages reported previously, we would add the lowering of social costs by means of reducing the length of hospital admissions and avoiding the attendance of the patient and relatives at the hospital for two days for each individual exploration. This policy would also facilitate the endoscopy room's workload planning, resulting in a more efficient organization of endoscopic resources.

But all these are theoretical advantages not previously proved since a prospective comparative study of single

versus a two session approach is lacking. Two feasibility studies have been published supporting the tandem approach^[5,6]. The first one published by Tarantino *et al*^[6] aimed to report the complication rate of performing EUS-FNA followed by ERCP in 25 patients with biliary or pancreatic disease. No early or late complications were seen in this series. The authors concluded that performing both explorations the same day was feasible and safe and should be considered the reference standard. Ross *et al*^[5] also published a feasibility retrospective study including 114 jaundiced patients who underwent EUS ± FNA followed by ERCP. They concluded that combined EUS and ERCP is a feasible approach to establish a tissue diagnosis, complete local staging and relieve biliary obstruction in a single session with a complication rate no greater than that for the component procedures.

These feasibility studies were preceded by discouraging clinical observations. Mergener *et al*^[2] published a case of a 77 year old woman who developed pneumoperitoneum after EUS-FNA of a peripancreatic lymph node followed by ERCP. This complication was asymptomatic and no intervention was required so the clinical importance of this observation remained unclear. The authors postulated that the pneumoperitoneum resulted from insufflated air tracking through the FNA site during ERCP and recommended that in a tandem approach, ERCP should precede FNA. Di Matteo *et al*^[3] reported two cases of biliary leakage complicating ERCP performed after EUS-FNA of a pancreatic head mass. They postulated that FNA would create subclinical bile duct injuries which would be aggravated by manipulation during ERCP. Furthermore, Fisher *et al* reported a significant association between myocardial ischemia or injury, defined by the release of cardiac troponin I, with a longer duration of ERCP (37.7 ± 28.9 min *vs* 24.2 ± 12.3 min in this study, $P = 0.007$). This was true only for patients older than 65 years and predominant in men. The critical time cut-off value in this study was 30 min of duration for ERCP. Although there are other investigators^[9,10] who, based on ECG intraoperative studies, concluded that, even in patients with severe coronary artery disease, ERCP and other endoscopic procedures do not increase the risk of myocardial ischemia. Taking into account these data, the benefits of the tandem approach would be questioned by a potentially higher risk of cardiac and endoscopic complications.

With this background, we decided to evaluate the benefits and complications of the tandem approach compared with the two session approach by means of a comparative retrospective study, including consecutive patients who underwent EUS and ERCP in our endoscopy unit for a 41 mo period. In our study, both groups were comparable regarding age, sex, indication for endoscopy and ASA grade, and no significant differences were seen regarding diagnostic yield, cardiopulmonary complications, endoscopic complications or procedural time between both groups. This latter aspect might be surprising since it has been previously postulated that the tandem approach would lower the procedure time^[5,6]. Ross *et al* reported a mean procedure time for the combined

procedure of 73.6 ± 30 min and Tarantino *et al* 58.6 ± 16.14 min. In our study, the mean intervention time for the tandem procedure reached 93 ± 32.78 min, lower although not significantly different than the mean 98.98 ± 38.17 min corresponding to the two session group. The explanation for this “high” procedure time can be found on the retrospective nature of our study since the procedural time we registered ranged from the moment the patient was monitored to the moment he left the endoscopic room which includes a large period without any endoscopic maneuver. In this sense, we think that our study does not properly clarify this aspect.

The only significant difference we found between both approaches was the propofol requirements, favoring the tandem approach which required a lower propofol dose. This is undoubtedly an important issue and supports the tandem approach, confirming the previous hypothesis raised by other authors^[5].

We performed EUS with FNA in 32 patients without related complications and with a diagnostic yield of 90.6%. No pneumoperitoneum or biliary leakage was detected after EUS-FNA and the only perforation in our series occurred in a patient in Group II.

The main limitation of our study lies in its retrospective nature, as already discussed. Moreover, it is a single center study including a heterogeneous group of patients, resulting in a selection bias since the decision to perform combined or separated EUS and ERCP depended on the referring physician. Referring clinicians were, in many cases, non-specialized gastroenterologists who were not implicated in the trial and many were not familiarized with the latest high-level endoscopic innovations. Therefore, their choice of exploration was determined either by their usual clinical practice or by the latest information on the subject that had reached them. This makes a selection bias which could not be controlled due to the characteristics of the study.

In conclusion, our results show that the performance of EUS followed by ERCP in a single session is feasible and safe, does not entail a higher cardiopulmonary or endoscopic complication risk and requires a significantly smaller dose of propofol for sedation compared with performing each exploration in two different sessions. Furthermore, the tandem approach does not lower the diagnostic yield of EUS or ERCP.

COMMENTS

Background

Nowadays patients with pancreatobiliary disease undergo endoscopic retrograde cholangiopancreatography (ERCP) and Endoscopic ultrasonography (EUS) more frequently as part of their diagnostic and therapeutic management. To perform both explorations in a single anesthetic and endoscopic session has been discouraged by some authors for a possible higher risk of complications.

Research frontiers

To our knowledge, the feasibility and outcomes of performing both explorations in the same session has never been compared with performing them in different endoscopic and anesthetic sessions.

Innovations and breakthroughs

The dose of Propofol administered to patients was the only variable significantly different when comparing both groups. Procedural time, incidence

of complications, diagnostic yield and therapeutic procedures showed no difference between the groups. This is an important finding since the major drawback described to perform ERCP and EUS in the same session was that it may increase the risk of perforation and systemic complications. This has not been confirmed in this study.

Applications

According to our data, to perform both explorations in a single session does not entail a higher risk of complication. This policy can have some advantages and may be important regarding costs and endoscopy room daily work plan organization. In any case, prospective and comparative studies are warranted.

Terminology

ERCP is an endoscopic procedure which allows drainage of the bile and pancreatic ducts through the papilla. It is also useful to diagnose biliary and pancreatic disease and to obtain material for cytological or histological analysis. EUS is also an endoscopic procedure which combines endoscopic and ultrasonographic view, with higher frequencies than transabdominal ultrasonography and thus with a higher resolution. It allows tissue to be obtained for pathological diagnosis and transmural therapeutic procedures to be performed with a low risk of complication.

Peer review

This paper describes a retrospective study of patients undergoing tandem EUS plus ERCP versus separate procedures. No difference was demonstrated in the outcome parameters.

REFERENCES

- 1 **Hollerbach S.** EUS and ERCP: brothers in arms. *Gastrointest Endosc* 2008; **68**: 467-469
- 2 **Mergener K,** Jowell P, Branch M, Baillie J. Pneumoperitoneum complicating ERCP performed immediately after EUS-guided fine needle aspiration. *Gastrointest Endosc* 1998;**47**:541-542.
- 3 **Di Matteo F,** Shimpi L, Gabbriellini A, Martino M, Caricato M, Esposito A, De Cicco ML, Coppola R, Costamagna G. Same-day endoscopic retrograde cholangiopancreatography after transduodenal endoscopic ultrasound-guided needle aspiration: do we need to be cautious? *Endoscopy* 2006; **38**: 1149-1151
- 4 **Fisher L,** Fisher A, Thomson A. Cardiopulmonary complications of ERCP in older patients. *Gastrointest Endosc* 2006; **63**: 948-955
- 5 **Ross WA,** Wasan SM, Evans DB, Wolff RA, Trapani LV, St-aerkel GA, Prindiville T, Lee JH. Combined EUS with FNA and ERCP for the evaluation of patients with obstructive jaundice from presumed pancreatic malignancy. *Gastrointest Endosc* 2008; **68**: 461-466
- 6 **Tarantino I,** Barresi L, Di Pisa M, Traina M. Simultaneous endoscopic ultrasound fine needle aspiration and endoscopic retrograde cholangio-pancreatography: Evaluation of safety. *World J Gastroenterol* 2007; **13**: 3861-3863
- 7 **Fusaroli P,** Manta R, Fedeli P, Maltoni S, Grillo A, Giovannini E, Bucchi L, Caletti G. The influence of endoscopic biliary stents on the accuracy of endoscopic ultrasound for pancreatic head cancer staging. *Endoscopy* 2007; **39**: 813-817
- 8 **Shami VM,** Mahajan A, Sundaram V, Davis EM, Loch MM, Kahaleh M. Endoscopic ultrasound staging is adversely affected by placement of a self-expandable metal stent: fact or fiction? *Pancreas* 2008; **37**: 396-398
- 9 **Cappell MS.** Endoscopic retrograde cholangiopancreatography with endoscopic sphincterotomy for symptomatic choledocholithiasis after recent myocardial infarction. *Am J Gastroenterol* 1996; **91**: 1827-1831
- 10 **Wilcox CM,** Faibicher M, Wenger NK, Shalek KA. Prevalence of silent myocardial ischemia and arrhythmias in patients with coronary heart disease undergoing gastrointestinal tract endoscopic procedures. *Arch Intern Med* 1993; **153**: 2325-2330

S- Editor Zhang HN L- Editor Roemmele A E- Editor Zhang L

Duodenal diverticulum and associated pancreatitis: Case report with brief review of literature

Mian Muhammad Rizwan, Harpeet Singh, VP Chandar, Maria Zulfiqar, Veera Singh

Mian Muhammad Rizwan, Harpeet Singh, VP Chandar, Maria Zulfiqar, Veera Singh, Department of Internal Medicine, Prince George's Hospital, MD 20785, United States

Author contributions: Rizwan MM, Singh H and Chandar VP supplemented the data about the patient; Zulfiqar M and Singh V reviewed the literature and analyzed the data; and Rizwan MM wrote the paper.

Correspondence to: Mian Muhammad Rizwan MD, Department of Internal Medicine, Prince George's Hospital, 3001 Hospital Drive, Cheverly, MD 20785,

United States. mmrizwan1@hotmail.com

Telephone: +1-301-6183776 Fax: +1-301-6182986

Received: August 30, 2010 Revised: December 25, 2010

Accepted: January 01, 2011

Published online: March 16, 2011

Department of Medicine, University Campus, 55 Lake Avenue, North, Worcester, MA 01655, United States

Rizwan MM, Singh H, Chandar VP, Zulfiqar M, Singh V. Duodenal diverticulum and associated pancreatitis: Case report with brief review of literature. *World J Gastrointest Endosc* 2011; 3(3): 62-63 Available from: URL: <http://www.wjgnet.com/1948-5190/full/v3/i3/62.htm> DOI: <http://dx.doi.org/10.4253/wjge.v3.i3.62>

Abstract

Pancreatitis in the elderly is a problem of increasing occurrence and is associated with severe complications. Periapillary diverticula (PAD) are extraluminal outpouchings of the duodenum rarely associated with pancreatitis. The presence of PAD should be excluded before diagnosing idiopathic pancreatitis, particularly in the elderly. However, when a duodenal diverticulum is found in the absence of any additional pathology, only then should the symptoms be attributed to the diverticulum. We describe a case of duodenal diverticulum presenting with pancreatitis to emphasize the importance of this commonly neglected etiology.

© 2011 Baishideng. All rights reserved.

Key words: Duodenal diverticulum; Periapillary duodenal diverticulum; Pancreatitis

Peer reviewers: Jiang-Fan Zhu, MD, Professor of Surgery, Department of General Surgery, East Hospital of Tongji University, Pudong, Shanghai 200120, China; Maher Aref Abbas, MD, FACS, FASCRS, Associate Professor of Surgery, Chief, Colon and Rectal Surgery, Center for Minimally Invasive Surgery, Kaiser Permanente, 4760 Sunset Blvd, third Floor, Los Angeles, CA 90027, United States; Wahid Wassef, MD, MPH, FACG, Professor of Medicine, Division of Gastroenterology,

INTRODUCTION

Duodenal diverticulum is a well known entity since the early eighteenth century when it was first reported by a French pathologist, Chomel, in 1710. The duodenum is the second most common site of diverticula in the small bowel following the jejunum^[1,2]. It is difficult to ascertain the true prevalence of duodenal diverticula; they are seen in 1%-6% of upper gastrointestinal contrast studies^[2,3], 12%-27% of endoscopic studies^[2,4] and in 15%-22% of autopsies. Diverticula are rare below age 40 and the prevalence rate increases with age.

Diverticula occur at weak spots in the duodenal wall such as the site of entry of the common bile duct, pancreatic duct and perivascular connective tissue sheath. The exact etiology is not clear; however, it might be the end result of disordered duodenal motility. Advancing age, progressive weakening of intestinal smooth muscles and increase in intraduodenal pressure may all encourage the outpouching of the duodenum.

About 70%-75% of all duodenal diverticula are periampullary. Diverticula arising within 2-3 cm radius of the ampulla but not containing it are referred to as juxtampullary diverticula. However, if the papilla arises within a diverticulum it is called an intradiverticular papilla. In the majority of cases, diverticula arise on the inner or pancreatic border of the duodenum. The possibility of PAD should be kept in mind while interpreting any bile duct imaging. It can create a filling defect in biliary passage; hence, can be mistaken for periampullary tumors or biliary stones. It can also be misinterpreted as pancreatic pseudocyst when it is large and fluid filled.




Figure 1 A duodenal diverticulum with ampulla. A: Computed tomography scan of abdomen with gas collection in pancreatic head representing periampullary diverticulum penetrating in pancreatic tissue; B: Periampullary diverticulum

CASE REPORT

A 69 year old Caucasian male presented to our hospital because of worsening abdominal pain for 3 d. The pain was initially in the upper abdomen but later radiated to the back. Epigastric tenderness was evident on physical examination. He had a history of similar painful episodes occurring infrequently for a few years but the pain had never been so severe. He had never previously sought medical attention for this pain. He also had a past medical history of constipation, hemorrhoids, dementia and hypertension.

The patient was given nil per mouth while workup for abdominal pain was started. His pancreatic enzymes were found to be elevated and a subsequent CT scan showed an irregular pancreatic outline consistent with pancreatitis. Interestingly, CT of the abdomen showed gas collection in the pancreatic head which raised the suspicion of a duodenal diverticulum. Sigmoid diverticulum and a small inguinal hernia were also incidental findings on the CT scan. HIDA scan was performed which showed normal transit of bile through the common bile duct (CBD).

A subsequent ERCP showed a duodenal diverticulum with ampulla in the mouth of diverticulum (Figure 1A, B). There was no evidence of any CBD stones or strictures on cannulation of the CBD. No intervention was needed since the patient's condition started to improve with conservative management and the patient was found to be doing well at his 1 year follow-up visit.

Pancreatitis in the elderly is a problem of increasing occurrence and is associated with severe complications. The possibility of the presence of PAD should be kept in mind in the differential of pancreatitis, particularly in the elderly population. In this patient, we believe chronic constipation was the factor responsible for hemorrhoids, sigmoid and duodenal diverticulum. The diverticulum might have been a major contributing factor in repeated attacks of mild self-resolving pancreatitis in the past.

DISCUSSION

With lengthening of the life span, diverticulosis has come to occupy a more important position in the sphere of clinical gastroenterology. The majority of duodenal diverticula are asymptomatic. Clinical presentation may be characterized by

non-specific abdominal symptoms. However, complications are responsible for presentation in most cases. When drainage in the neck is inadequate or the neck is narrow, these conditions favor inflammation and may even lead to hemorrhage or perforation.

There have been anecdotal accounts implicating PAD in the pathogenesis of acute and chronic pancreatitis. Compression of CBD, dysfunction of the ampulla or a poorly emptying diverticulum with a narrow neck can all lead to pancreatico-biliary disease and possible pancreatitis. However, the relationship with pancreatitis remains tenuous as biliary calculus disease is also more common in PAD. It is debatable whether the pancreatitis is caused by the PAD per se or by the associated biliary calculi. It has been proposed that PAD may be responsible for transient biliary symptoms and alterations in liver function^[5]. It is possible in the above mentioned case that distension of a diverticulum with inspissated food might have caused compression of the pancreatic duct leading to pancreatitis which resolved spontaneously.

To date, there are no hard and fast guidelines regarding management of such diverticulum. Earlier this century, surgical diverticulectomy was frequently carried out for non-specific symptoms. There is now consensus that elective surgical treatment of asymptomatic or minimally symptomatic diverticulum is not justified. Operative procedures for diverticula in the second part of duodenum are particularly cumbersome since often it requires mobilization of the duodenum which is retroperitoneal. Dennesen and Rijken reviewed 45 reported cases of perforation of duodenal diverticula and found an overall mortality rate of 31%^[2]. Surgical or endoscopic interventions should only be reserved for symptomatic diverticulum^[6]. Diverticulectomy for vague pain and abdominal discomfort is dangerous and unrewarding; it carries a high morbidity and mortality^[3,6]. Furthermore, only 50% of patients treated with diverticulectomy were relieved of their symptoms^[6,7].

REFERENCES

- 1 Mahajan SK, Kashyap R, Chandel UK, Mokta J, Minhas SS. Duodenal diverticulum: Review of literature. *In J Surg* 2004; **66**: 140-145
- 2 Dennesen PJ, Rijken J. Duodenal diverticulitis. *Neth J Med* 1997; **50**: 250-253
- 3 Burgess CM, Ball J. Complications of surgery on duodenal diverticula. *Surg Clin North Am* 1970; **50**: 351-355
- 4 Zoepf T, Zoepf DS, Arnold JC, Benz C, Riemann JF. The relationship between juxtapapillary duodenal diverticula and disorders of the biliopancreatic system: analysis of 350 patients. *Gastrointest Endosc* 2001; **54**: 56-61
- 5 Lobo DN, Balfour TW, Iftikhar SY, Rowlands BJ. Periampullary diverticula and pancreaticobiliary disease. *Br J Surg* 1999; **86**: 588-597
- 6 Mathis KL, Farley DR. Operative management of symptomatic duodenal diverticula. *Am J Surg* 2007; **193**: 305-308; discussion 308-309
- 7 Harford WV. Diverticula of the hypopharynx and esophagus, the stomach and small bowel. In: Feldman M, Scharschmidt BF, Sieisenger and Fordtran's Gastrointestinal and Liver Diseases. 6th (Ed). Philadelphia: WB Saunders Co 1998: **1**: 313-316

S- Editor Zhang HN L- Editor Roemmele A E- Editor Liu N

Stent-in-stent through a side hole to prevent biliary metallic stent migration

Wiriyaoporn Ridditid, Rungsun Rerknimitr, Surachai Amornsawadwattana, Yuwadee Ponauthai, Pinit Kullavanijaya

Wiriyaoporn Ridditid, Rungsun Rerknimitr, Surachai Amornsawadwattana, Yuwadee Ponauthai, Pinit Kullavanijaya, Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
Author contributions: Ridditid W and Rerknimitr R contributed equally to this work; Ridditid W and Rerknimitr R developed the concept; Ridditid W, Rerknimitr R; Amornsawadwattana S and Ponauthai Y contributed to acquisition of data; Rerknimitr R and Kullavanijaya P revised the paper for important intellectual content; and Ridditid W and Rerknimitr R wrote the paper.

Correspondence to: Wiriyaoporn Ridditid, MD, Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand. wiriyaoporn_r@yahoo.com
Telephone: +66-2-2564265 Fax: +66-2-2527839
Received: November 1, 2010 Revised: December 17, 2010
Accepted: December 24, 2010
Published online: March 16, 2011

Abstract

The covered self-expandable metallic stent (SEMS) has been developed to overcome the problem of tissue ingrowth. However, stent migration is a well-known complication of covered SEMS placement. Use of a double pigtail stent to lock the movement of the SEMS and prevent migration has been advised by many experts. Unfortunately, in our case this technique led to an incidental upward migration of the SEMS. We used APC to create a side hole in the SEMS for plastic stent insertion as stent-in-stent. This led to a successful prevention of stent migration.

© 2011 Baishideng. All rights reserved.

Key words: Metallic stent migration; Distal biliary obstruction

Peer reviewers: Tony Chiew Keong Tham, MD, Consultant Gastroenterologist, Ulster Hospital, Dundonald, Belfast BT16 1RH, Northern Ireland, United Kingdom; Iruru Maetani, MD, Professor and Chairman, Division of Gastroenterology, Depart-

ment of Internal Medicine, Toho University Ohashi Medical Center, 2-17-6 Ohashi Meguro-ku, Tokyo 153-8515, Japan

Ridditid W, Rerknimitr R, Amornsawadwattana S, Ponauthai Y, Kullavanijaya P. Stent-in-stent through a side hole to prevent biliary metallic stent migration. *World J Gastrointest Endosc* 2011; 3(3): 64-66 Available from: URL: <http://www.wjgnet.com/1948-5190/full/v3/i3/64.htm> DOI: <http://dx.doi.org/10.4253/wjge.v3.i3.64>

INTRODUCTION

Self-expandable metallic stent (SEMS) placement is widely accepted for palliative management of patients with unresectable malignant biliary obstruction. However, complications such as tumor ingrowth, overgrowth, food debris, and mucosal hyperplasia can occur. The use of covered SEMS is clearly effective in preventing tumor ingrowth^[1-3]. Nevertheless, in two recently published randomized trials of covered versus uncovered metal biliary stents, outcomes such as stent patency were no different between the two stents but the risk of migration was higher with the covered stents^[4,5]. Here, we report a case of stent-in-stent insertion through a side hole to prevent migration of a covered self-expandable metallic stent in a patient with distal malignant biliary obstruction.

CASE REPORT

A 35-year-old man presented with obstructive jaundice resulting from metastatic pancreatic cancer. The diagnosis was confirmed by intraductal biopsy. Endoscopic retrograde cholangiopancreatography (ERCP) demonstrated a distal biliary stricture 1.5 cm in length with upstream dilatation. Placement of a 4-cm-long covered SEMS (Wallstent, Boston Scientific, Natick, MA) under conscious sedation was initially performed. Three weeks later, the patient was re-admitted due to acute cholangitis. ERCP demonstrated distal migration of the SEMS (Fi-




Figure 1 Endoscopic retrograde cholangio-pancreatography after re-admission. A: Distal migration of self-expandable metallic stent (SEMS); B: 8-cm-long partially covered SEMS replacement; C: Retrieving the stent using a rat-toothed forceps after upward migration of SEMS.




Figure 2 Stent-in-stent through the side hole. A: Creating a side hole at the distal end of the self-expandable metallic stent with argon plasma coagulation trimming; B: Insertion of plastic stent through the side hole; C: After the successful procedure for the prevention of stent migration.

Figure 1A). Successful removal of the first SEMS was performed using a snare and this was replaced with a new SEMS (Wallstent, Boston Scientific, Natick, MA), 8 cm in length (Figure 1B). Subsequently, placement of a double pigtail 10 Fr 10 cm plastic stent (PS) was attempted as stent-in-stent to prevent migration. However, even with cautious deployment the SEMS was accidentally displaced upwards during PS insertion. Using a rat-toothed forceps we were able to move the stent downwards to the proper position (Figure 1C). Argon plasma coagulation (APC) was then applied to create a side hole at the distal end of the SEMS (Figure 2A) and a PS was inserted through the side hole (Figure 2B). This side hole insertion was helpful in preventing the upward movement of the previously deployed SEMS (Figure 2C). Six months later the patient was doing well and was without clinical sign of biliary obstruction.

DISCUSSION

Covered SEMS placement is widely accepted for use in palliative management of patients with unresectable malignant distal biliary obstruction. Although covered stents are designed to overcome tissue ingrowth, failure to embed in the bile duct wall can result in proximal and distal migration, at a reported frequency of 6%-8%^[1-5]. Migration of a biliary SEMS may occur proximally or distally after stent insertion and may cause complications such as ulceration, perforation and intestinal obstruction^[1-3].

Generally, correct positioning of the SEMS at the initial stent placement is important in preventing migration. Nevertheless, a high shortening ratio of the covered

SEMS is thought to favour migration after deployment of the stent^[6]. New covered stents, therefore, have been developed for the prevention of stent migration. These include the nitinol SEMS (Wallflex; Boston Scientific, Natick, Massachusetts, USA or Niti-S; Taewoong Medical, Seoul, South Korea) which is flared at the uncovered ends and the fully-covered Zeostent (Zeon Medical Inc., Tokyo, Japan) which has a wavy contour after full expansion^[6,7]. Some previous work of expert endoscopists suggested that putting a double pigtail stent as stent-in-stent to lock the movement of the SEMS could prevent migration^[8]. However, this technique for preventing biliary stent migration has not been well established. We have reported a case with malignant distal biliary obstruction after covered SEMS placement. In our case, the insertion of a double pigtail stent was performed to lock the movement of the SEMS and thereby prevent its migration. However, due to upward force exerted during PS insertion as stent-in-stent, this technique led to an incidental upward migration of the covered SEMS.

Argon plasma (APC) has been described as a useful tool for trimming the stent or making a hole^[9-12]. Studies done on Wallstent, have recommended a power setting of 70-80 W and argon flow of 0.8 L/min. In this case, we used APC to make a side hole in the SEMS for PS insertion without complication. After the force angle of PS insertion was changed, the distal end of double pigtail stent was able to lock the distal end of the SEMS and to prevent upward migration of SEMS during PS placement.

In conclusion, we report a successful technique of stent-in-stent insertion through the side hole to change

an angle of PS insertion for preventing upward covered SEMS migration in a patient with distal malignant biliary obstruction. With this tangential stent insertion, the chance of upward stent migration during deployment should be less.

REFERENCES

- 1 **Isayama H**, Nakai Y, Togawa O, Kogure H, Ito Y, Sasaki T, Sasahira N, Hirano K, Tsujino T, Tada M, Kawabe T, Omata M. Covered metallic stents in the management of malignant and benign pancreatobiliary strictures. *J Hepatobiliary Pancreat Surg* 2009; **16**: 624-627
- 2 **Nakai Y**, Isayama H, Komatsu Y, Tsujino T, Toda N, Sasahira N, Yamamoto N, Hirano K, Tada M, Yoshida H, Kawabe T, Omata M. Efficacy and safety of the covered Wallstent in patients with distal malignant biliary obstruction. *Gastrointest Endosc* 2005; **62**: 742-748
- 3 **Leung J**, Rahim N. The role of covered self-expandable metallic stents in malignant biliary strictures. *Gastrointest Endosc* 2006; **63**: 1001-1003
- 4 **Telford JJ**, Carr-Locke DL, Baron TH, Poneris JM, Bounds BC, Kelsey PB, Schapiro RH, Huang CS, Lichtenstein DR, Jacobson BC, Saltzman JR, Thompson CC, Forcione DG, Gostout CJ, Brugge WR. A randomized trial comparing uncovered and partially covered self-expandable metal stents in the palliation of distal malignant biliary obstruction. *Gastrointest Endosc* 2010; **72**: 907-914
- 5 **Kullman E**, Frozanpor F, Söderlund C, Linder S, Sandström P, Lindhoff-Larsson A, Toth E, Lindell G, Jonas E, Freedman J, Ljungman M, Rudberg C, Ohlin B, Zacharias R, Leijonmarck CE, Teder K, Ringman A, Persson G, Gözen M, Eriksson O. Covered versus uncovered self-expandable nitinol stents in the palliative treatment of malignant distal biliary obstruction: results from a randomized, multicenter study. *Gastrointest Endosc* 2010; **72**: 915-923
- 6 **Ito K**, Fujita N, Noda Y, Kobayashi G, Obana T, Horaguchi J, Koshita S, Kanno Y, Ogawa T, Kato Y, Yamashita Y. Newly developed fully covered metal stent for unresectable malignant biliary stricture. *Diagn Ther Endosc* 2010; **2010**: 903520
- 7 **Rajjman I**. Biliary and pancreatic stents. *Gastrointest Endosc Clin N Am* 2003; **13**: 561-592, vii-viii
- 8 **Talreja JP**, Shami VM, Ku J, Morris TD, Ellen K, Kahaleh M. Transenteric drainage of pancreatic-fluid collections with fully covered self-expanding metallic stents (with video). *Gastrointest Endosc* 2008; **68**: 1199-1203
- 9 **Rerknimitr R**, Naprasert P, Kongkam P, Kullavanijaya P. Trimming a metallic biliary stent using an argon plasma coagulator. *Cardiovasc Intervent Radiol* 2007; **30**: 534-536
- 10 **Christiaens P**, Decock S, Buchel O, Bulté K, Moons V, D'Haens G, Van Olmen G. Endoscopic trimming of metallic stents with the use of argon plasma. *Gastrointest Endosc* 2008; **67**: 369-371
- 11 **Vanbiervliet G**, Piche T, Caroli-Bosc FX, Dumas R, Peten EP, Huet PM, Tran A, Demarquay JF. Endoscopic argon plasma trimming of biliary and gastrointestinal metallic stents. *Endoscopy* 2005; **37**: 434-438
- 12 **Matsubayashi H**, Hasuike N, Tanaka M, Takizawa K, Yamaguchi Y, Ono H. Trimming of a migrated nitinol stent using argon plasma. *Case Rep Gastroenterol* 2009; **3**: 202-206

S- Editor Zhang HN L- Editor Hughes D E- Editor Liu N

Acknowledgments to reviewers of *World Journal of Gastrointestinal Endoscopy*

Many reviewers have contributed their expertise and time to the peer review, a critical process to ensure the quality of *World Journal of Gastrointestinal Endoscopy*. The editors and authors of the articles submitted to the journal are grateful to the following reviewers for evaluating the articles (including those published in this issue and those rejected for this issue) during the last editing time period.

Maher Aref Abbas, MD, FACS, FASCRS, Associate Professor of Surgery, Chief, Colon and Rectal Surgery, Chair, Center for Minimally Invasive Surgery, Kaiser Permanente, 4760 Sunset Blvd, third Floor, Los Angeles, CA 90027, United States

Iru Maetani, MD, Professor and Chairman, Division of Gastroenterology, Department of Internal Medicine, Toho University Ohashi Medical Center, 2-17-6 Ohashi Meguro-ku, Tokyo 153-8515, Japan

Lucian Negreanu, MD, PhD, Assistant Professor, Gastroenterology Department, Emergency University Hospital, Carol Davila

University Bucharest, 169 splaiul Independentei Street, sector 5, Bucharest, Romania

Michal Procke, MD, Department of Internal Medicine - Gastroenterology and Endoscopy, Charles University, 2nd Medical School, Motol University Hospital, Prague, Czech Republic

Perminder Phull, MD, FRCP, FRCPE, Gastrointestinal & Liver Service, Room 2.58, Ashgrove House, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN, United Kingdom

Tony Chiew Keong Tham, MD, Consultant Gastroenterologist, Ulster Hospital, Dundonald, Belfast BT16 1RH, Northern Ireland, United Kingdom

Wahid Wassef, MD, MPH, FACG, Professor of Medicine, Division of Gastroenterology, Department of Medicine, University Campus, 55 Lake Avenue, North, Worcester, MA 01655, United States

Jiang-Fan Zhu, MD, Professor of surgery, Department of General Surgery, East Hospital of Tongji University, Pudong, Shanghai 200120, China

Meetings

Events Calendar 2011

January 14-15, 2011
AGA Clinical Congress of
Gastroenterology and Hepatology:
Best Practices in 2011
Miami, FL 33101, United States

January 20-22, 2011
Gastrointestinal Cancers Symposium
2011
San Francisco, CA 94143,
United States

January 28-29, 2011
9. Gastro Forum München
Munich, Germany

February 04-05, 2011
13th Duesseldorf International
Endoscopy Symposium
Duesseldorf, Germany

February 13-27, 2011
Gastroenterology: New Zealand
CME Cruise Conference
Sydney, NSW, Australia

February 24-26, 2011
Inflammatory Bowel Diseases
2011-6th Congress of the European
Crohn's and Colitis Organisation
Dublin, Ireland

February 24-26, 2011
2nd International Congress on
Abdominal Obesity
Buenos Aires, Brazil

February 26-March 1, 2011
Canadian Digestive Diseases Week
Westin Bayshore, Vancouver
British Columbia, Canada

March 03-05, 2011
42nd Annual Topics in Internal
Medicine
Gainesville, FL 32614,
United States

March 14-17, 2011
British Society of Gastroenterology
Annual Meeting 2011
Birmingham, England, United
Kingdom

March 17-19, 2011
41. Kongress der Deutschen
Gesellschaft für Endoskopie und
Bildgebende Verfahren e.V.
Munich, Germany

March 17-20, 2011
Mayo Clinic Gastroenterology &
Hepatology 2011
Jacksonville, FL 34234, United States

March 25-27, 2011
MedicReS IC 2011 Good Medical
Research
Istanbul, Turkey

April 07-09, 2011
International and Interdisciplinary
Conference Excellence in Female
Surgery
Florence, Italy

April 15-16, 2011
Falk Symposium 177, Endoscopy
Live Berlin 2011 Intestinal Disease
Meeting, Stauffenbergstr. 26
Berlin 10785, Germany

April 18-22, 2011
Pediatric Emergency Medicine:
Detection, Diagnosis and Developing
Treatment Plans
Sarasota, FL 34234, United States

April 20-23, 2011
9th International Gastric Cancer
Congress, COEX, World Trade
Center, Samseong-dong
Seoul 135-731, South Korea

April 25-27, 2011
The Second International Conference
of the Saudi Society of Pediatric
Gastroenterology, Hepatology &
Nutrition
Riyadh, Saudi Arabia

April 28-30, 2011
4th Central European Congress of
Surgery
Budapest, Hungary

May 07-10, 2011
Digestive Disease Week
Chicago, IL 60446, United States

May 12-13, 2011
2nd National Conference Clinical
Advances in Cystic Fibrosis
London, England, United Kingdom

May 21-24, 2011
22nd European Society of
Gastrointestinal and Abdominal
Radiology Annual Meeting and
Postgraduate Course
Venice, Italy

May 25-28, 2011
4th Congress of the Gastroenterology
Association of Bosnia and

Herzegovina with international
participation, Hotel Holiday Inn
Sarajevo, Bosnia and Herzegovina

June 11-12, 2011
The International Digestive Disease
Forum 2011
Hong Kong, China

June 13-16, 2011
Surgery and Disillusion XXIV Spig
II ESYS, Napoli, Italy

June 22-25, 2011
ESMO Conference: 13th World
Congress on Gastrointestinal Cancer
Barcelona, Spain

September 10-11, 2011
New Advances in Inflammatory
Bowel Disease
La Jolla, CA 92093, United States

September 10-14, 2011
ICE 2011-International Congress of
Endoscopy, Los Angeles Convention
Center, 1201 South Figueroa Street
Los Angeles, CA 90015, United
States

September 30-October 1, 2011
Falk Symposium 179, Revisiting
IBD Management: Dogmas to be
Challenged, Sheraton Brussels Hotel
Brussels 1210, Belgium

October 19-29, 2011
Cardiology & Gastroenterology
Tahiti 10 night CME Cruise
Papeete, French Polynesia

October 22-26, 2011
19th United European
Gastroenterology Week
Stockholm, Sweden

October 28-November 02, 2011
ACG Annual Scientific Meeting &
Postgraduate Course
Washington, DC 20001, United
States

November 11-12, 2011
Falk Symposium 180, IBD 2011:
Progress and Future for Lifelong
Management, ANA Interconti Hotel,
1-12-33 Akasaka, Minato-ku
Tokyo 107-0052, Japan

December 01-04, 2011
2011 Advances in Inflammatory
Bowel Diseases/Crohn's & Colitis
Foundation's Clinical & Research
Conference
Hollywood, FL 34234, United States

Instructions to authors

GENERAL INFORMATION

World Journal of Gastrointestinal Endoscopy (*World J Gastrointest Endosc*, *WJGE*, online ISSN 1948-5190, DOI: 10.4253), is a monthly, open-access (OA), peer-reviewed online journal supported by an editorial board of 400 experts in gastrointestinal endoscopy from 45 countries.

The biggest advantage of the OA model is that it provides free, full-text articles in PDF and other formats for experts and the public without registration, which eliminates the obstacle that traditional journals possess and usually delays the speed of the propagation and communication of scientific research results.

Maximization of personal benefits

The role of academic journals is to exhibit the scientific levels of a country, a university, a center, a department, and even a scientist, and build an important bridge for communication between scientists and the public. As we all know, the significance of the publication of scientific articles lies not only in disseminating and communicating innovative scientific achievements and academic views, as well as promoting the application of scientific achievements, but also in formally recognizing the "priority" and "copyright" of innovative achievements published, as well as evaluating research performance and academic levels. So, to realize these desired attributes of *WJGE* and create a well-recognized journal, the following four types of personal benefits should be maximized. The maximization of personal benefits refers to the pursuit of the maximum personal benefits in a well-considered optimal manner without violation of the laws, ethical rules and the benefits of others. (1) Maximization of the benefits of editorial board members: The primary task of editorial board members is to give a peer review of an unpublished scientific article via online office system to evaluate its innovativeness, scientific and practical values and determine whether it should be published or not. During peer review, editorial board members can also obtain cutting-edge information in that field at first hand. As leaders in their field, they have priority to be invited to write articles and publish commentary articles. We will put peer reviewers' names and affiliations along with the article they reviewed in the journal to acknowledge their contribution; (2) Maximization of the benefits of authors: Since *WJGE* is an open-access journal, readers around the world can immediately download and read, free of charge, high-quality, peer-reviewed articles from *WJGE* official website, thereby realizing the goals and significance of the communication between authors and peers as well as public reading; (3) Maximization of the benefits of readers: Readers can read or use, free of charge, high-quality peer-reviewed articles without any limits, and cite the arguments, viewpoints, concepts, theories, methods, results, conclusion or facts and data of pertinent literature so as to validate the innovativeness, scientific and practical values of their own research achievements, thus ensuring that their articles have novel arguments or viewpoints, solid evidence and correct conclusion; and (4) Maximization of the benefits of employees: It is an iron law that a first-class journal is unable to exist without first-class editors, and only first-class editors can create a first-class academic journal. We insist on strengthening our team cultivation and construction so that every employee, in an open, fair and transparent environment, could contribute their wisdom to edit and publish high-quality articles, thereby realizing the maximization of the personal benefits of editorial board members, authors and readers, and yielding the greatest social and economic benefits.

Aims and scope

The major task of *WJGE* is to report rapidly the most recent results in basic and clinical research on gastrointestinal endoscopy including: gastroscopy, intestinal endoscopy, colonoscopy, capsule endoscopy, laparoscopy, interventional diagnosis and therapy, as well as advances in technology. Emphasis is placed on the clinical practice of treating gastrointestinal diseases with or under endoscopy. Papers on advances and application of endoscopy-associated techniques, such as endoscopic ultrasonography, endoscopic retrograde cholangiopancreatography, endoscopic submucosal dissection and endoscopic balloon dilation are also welcome.

Columns

The columns in the issues of *WJGE* will include: (1) Editorial: To introduce and comment on major advances and developments in the field; (2) Frontier: To review representative achievements, comment on the state of current research, and propose directions for future research; (3) Topic Highlight: This column consists of three formats, including (A) 10 invited review articles on a hot topic, (B) a commentary on common issues of this hot topic, and (C) a commentary on the 10 individual articles; (4) Observation: To update the development of old and new questions, highlight unsolved problems, and provide strategies on how to solve the questions; (5) Guidelines for Basic Research: To provide guidelines for basic research; (6) Guidelines for Clinical Practice: To provide guidelines for clinical diagnosis and treatment; (7) Review: To review systemically progress and unresolved problems in the field, comment on the state of current research, and make suggestions for future work; (8) Original Article: To report innovative and original findings in gastrointestinal endoscopy; (9) Brief Article: To briefly report the novel and innovative findings in gastrointestinal endoscopy; (10) Case Report: To report a rare or typical case; (11) Letters to the Editor: To discuss and make reply to the contributions published in *WJGE*, or to introduce and comment on a controversial issue of general interest; (12) Book Reviews: To introduce and comment on quality monographs of gastrointestinal endoscopy; and (13) Guidelines: To introduce consensus and guidelines reached by international and national academic authorities worldwide on basic research and clinical practice in gastrointestinal endoscopy.

Name of journal

World Journal of Gastrointestinal Endoscopy

Serial publication number

ISSN 1948-5190 (online)

Indexed and Abstracted in

PubMed Central, PubMed, Digital Object Identifier, and Directory of Open Access Journals.

Published by

Baishideng Publishing Group Co., Limited

SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics from to evaluate the statistical method used

Instructions to authors

in the paper, including *t*-test (group or paired comparisons), chi-squared test, Ridit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJGE* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: http://www.icmje.org/ethical_4conflicts.html.

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the International Committee of Medical Journal Editors to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

Online submissions

Manuscripts should be submitted through the Online Submission System at: wjge@wjgnet.com. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS (http://www.wjgnet.com/1948-5190/g_info_20100316080002.htm) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to <http://www.wjgnet.com/1948-5190office/>, or by telephone: +86-10-59080038. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

Title page

Title: Title should be less than 12 words.

Running title: A short running title of less than 6 words should be provided.

Authorship: Authorship credit should be in accordance with the standard proposed by International Committee of Medical Journal Editors, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

Institution: Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for

example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

Author contributions: The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

Supportive foundations: The complete name and number of supportive foundations should be provided, e.g., Supported by National Natural Science Foundation of China, No. 30224801

Correspondence to: Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. montgomery.bissell@ucsf.edu

Telephone and fax: Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g., Telephone: +86-10-59080039 Fax: +86-10-85381893

Peer reviewers: All articles received are subject to peer review. Normally, three experts are invited for each article. Decision for acceptance is made only when at least two experts recommend an article for publication. Reviewers for accepted manuscripts are acknowledged in each manuscript, and reviewers of articles which were not accepted will be acknowledged at the end of each issue. To ensure the quality of the articles published in *WJGE*, reviewers of accepted manuscripts will be announced by publishing the name, title/position and institution of the reviewer in the footnote accompanying the printed article. For example, reviewers: Professor Jing-Yuan Fang, Shanghai Institute of Digestive Disease, Shanghai, Affiliated Renji Hospital, Medical Faculty, Shanghai Jiaotong University, Shanghai, China; Professor Xin-Wei Han, Department of Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China; and Professor Anren Kuang, Department of Nuclear Medicine, Huaxi Hospital, Sichuan University, Chengdu, Sichuan Province, China.

Abstract

There are unstructured abstracts (no more than 256 words) and structured abstracts (no more than 480). The specific requirements for structured abstracts are as follows:

An informative, structured abstracts of no more than 480 words should accompany each manuscript. Abstracts for original contributions should be structured into the following sections. AIM (no more than 20 words): Only the purpose should be included. Please write the aim as the form of "To investigate/study/..."; MATERIALS AND METHODS (no more than 140 words); RESULTS (no more than 294 words): You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g. 6.92 ± 3.86 vs 3.61 ± 1.67 , $P < 0.001$; CONCLUSION (no more than 26 words).

Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

Text

For articles of these sections, original articles, rapid communica-

tion and case reports, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at: http://www.wjgnet.com/1948-5190/g_info_20100316080002.htm.

Illustrations

Figures should be numbered as 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Figures should be either Photoshop or Illustrator files (in tiff, eps, jpeg formats) at high-resolution. Examples can be found at: <http://www.wjgnet.com/1007-9327/13/4520.pdf>; <http://www.wjgnet.com/1007-9327/13/4554.pdf>; <http://www.wjgnet.com/1007-9327/13/4891.pdf>; <http://www.wjgnet.com/1007-9327/13/4986.pdf>; <http://www.wjgnet.com/1007-9327/13/4498.pdf>. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...etc. It is our principle to publish high resolution-figures for the printed and E-versions.

Tables

Three-line tables should be numbered 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

Notes in tables and illustrations

Data that are not statistically significant should not be noted. ^a*P* < 0.05, ^b*P* < 0.01 should be noted (*P* > 0.05 should not be noted). If there are other series of *P* values, ^c*P* < 0.05 and ^d*P* < 0.01 are used. A third series of *P* values can be expressed as ^e*P* < 0.05 and ^f*P* < 0.01. Other notes in tables or under illustrations should be expressed as ¹F, ²F, ³F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, etc., in a certain sequence.

Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

REFERENCES

Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability^[1,2]". If references are cited directly in the text, they should be put together within the text, for example, "From references^[19,22-24], we know that..."

When the authors write the references, please ensure that

Instructions to authors

the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

PMID and DOI

Pleased provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

Format

Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarhoea. *Shijie Huaren Xiaobua Zazhi* 1999; **7**: 285-287

In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMCID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/

j.1526-4610.42.s2.7.x]

Issue with no volume

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; (**401**): 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS A Careaction* 2002; 1-6 [PMID: 12154804]

Books

Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

Chapter in a book (list all authors)

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

Author(s) and editor(s)

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wicczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

Conference proceedings

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

Conference paper

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

Statistical data

Write as mean \pm SD or mean \pm SE.

Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as χ^2 (in Greek), related coefficient as *r* (in italics), degree of freedom as ν (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h, blood glucose concentration, *c* (glucose) 6.4 ± 2.1 mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 $24.5 \mu\text{g/L}$; CO₂ volume fraction, 50 mL/L CO₂, not 5% CO₂; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, etc. Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantities can be found at: <http://www.wjgnet.com/wjg/help/15.doc>

Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols

and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, etc.

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kho I*, *Kpn I*, etc.

Biology: *H. pylori*, *E. coli*, etc.

Examples for paper writing

Editorial: http://www.wjgnet.com/1948-5190/g_info_20100316080004.htm

Frontier: http://www.wjgnet.com/1948-5190/g_info_20100313155344.htm

Topic highlight: http://www.wjgnet.com/1948-5190/g_info_20100316080006.htm

Observation: http://www.wjgnet.com/1948-5190/g_info_201007124105.htm

Guidelines for basic research: http://www.wjgnet.com/1948-5190/g_info_20100313155908.htm

Guidelines for clinical practice: http://www.wjgnet.com/1948-5190/g_info_20100313160015.htm

Review: http://www.wjgnet.com/1948-5190/g_info_201007124313.htm

Original articles: http://www.wjgnet.com/1948-5190/g_info_201007133454.htm

Brief articles: http://www.wjgnet.com/1948-5190/g_info_20100313160645.htm

Case report: http://www.wjgnet.com/1948-5190/g_info_201007133659.htm

Letters to the editor: http://www.wjgnet.com/1948-5190/g_info_201007133856.htm

Book reviews: http://www.wjgnet.com/1948-5190/g_info_20100313161146.htm

Guidelines: http://www.wjgnet.com/1948-5190/g_info_20100313161315.htm

SUBMISSION OF THE REVISED MANUSCRIPTS AFTER ACCEPTED

Please revise your article according to the revision policies of *WJGE*. The revised version including manuscript and high-resolution image figures (if any) should be copied on a floppy or compact disk. The author should send the revised manuscript, along with printed high-resolution color or black and white photos, copyright transfer letter, and responses to the reviewers by courier (such as EMS/DHL).

Editorial Office

World Journal of Gastrointestinal Endoscopy

Editorial Department: Room 903, Building D,

Ocean International Center,

No. 62 Dongsihuan Zhonglu,

Chaoyang District, Beijing 100025, China

E-mail: wjge@wjgnet.com

<http://www.wjgnet.com>

Telephone: +86-10-59080038

Fax: +86-10-85381893

Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A or B.

Copyright assignment form

Please download a Copyright assignment form from http://www.wjgnet.com/1948-5190/g_info_20100107134847.htm.

Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: http://www.wjgnet.com/1948-5190/g_info_20100107134601.htm.

Proof of financial support

For paper supported by a foundation, authors should provide a copy of the document and serial number of the foundation.

Links to documents related to the manuscript

WJGE will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

Science news releases

Authors of accepted manuscripts are suggested to write a science news item to promote their articles. The news will be released rapidly at EurekaAlert/AAAS (<http://www.eurekaalert.org>). The title for news items should be less than 90 characters; the summary should be less than 75 words; and main body less than 500 words. Science news items should be lawful, ethical, and strictly based on your original content with an attractive title and interesting pictures.

Publication fee

WJGE is an international, peer-reviewed, Open-Access, online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. The related standards are as follows. Publication fee: 1300 USD per article. Editorial, topic highlights, book reviews and letters to the editor are published free of charge.